



सत्यमेव जयते



क.रा.बी.नि.
ESIC

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

DG-ESIC CENTRAL RATE CONTRACT NO. – 166
FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 11th DECEMBER, 2025 to 10th DECEMBER, 2027)

DRUGS FOR RESPIRATORY SYSTEM
DRUGS FOR CARDIO-VASCULAR SYSTEM
DRUGS ACTING ON CENTRAL NERVOUS SYSTEM

STRICTLY FOR OFFICIAL USE

मुख्यालय/HEADQUARTERS'

कमरा नंबर 312 और 321, तीसरी मंजिल, पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002

Room No. 312 & 321, 3rd Floor, Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002

www.esic.gov.in, ☎ 011-23604773, ✉ dmc-rc@esic.gov.in



क.स.बी.नि.
E S I C

S.No.	Contents	Page No.
1.	Forwarding letter along with terms & conditions for operation of Rate Contract No. 166	1-12
2.	List of Approved Pharmaceutical firms of Rate Contract No. 166	13-18
3.	Indexing of approved Items	19-27
4.	Rate Schedule of Rate Contract No. 166	28-57

क.स.बी.नि.
E S I C

STRICTLY FOR OFFICIAL USE ONLY



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 www.esic.gov.in,
☎011-23604773, ✉ dmc-rc@esic.gov.in

No. U-25/12/165 to 169/2024-Medical.V (E-754406)/166 (RC-166)

Dated: 12.12.2025

From:

The Director General,
E.S.I. Corporation,
Panchdeep Bhawan,
C.I.G Road,
NEW DELHI - 110 002.

To

Director (Medical) Delhi/Noida
Dean-PGIMSR's/ All ESIC Medical Colleges & Hospitals/Dental Colleges
Medical Superintendent – All ESIC & ESIS Hospitals,
Director, ESI Scheme – All States & UTs.

Sub: **PROCUREMENT OF DRUGS UNDER ESIC CENTRAL RATE CONTRACT NO. 166 EFFECTIVE FROM 11.12.2025 TO 10.12.2027.**

Sir / Madam,

Please find enclosed a copy of the DG-ESIC Centralized Rate Contract duly adhering to Public Procurement (Preference to Make in India) Order, 2017 (as amended and revised till date) and related notifications from the relevant Nodal Ministry/ Department, finalized for supply of Drugs under the ESI Scheme in the country.

Validity of this Rate Contract is for a period of two years i.e. w.e.f. 11.12.2025 TO 10.12.2027.

Further, the following terms & conditions are issued to govern operation of the Rate Contract:

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers- Medical Superintendent/Dean/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his/her behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

2. Supply orders will be placed by Medical Superintendents/Deans/Director, Insurance Medical Services of various States, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and / or wherever specifically provided in the terms & conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract.
3. All the supply orders shall be signed only by the officers who have been duly authorized and included in the list of DDOs. **DDOs will send scanned copy of the Purchase Order mandatorily through email followed by speed post directly to the Approved Pharmaceutical Firm. The due date of delivery will be counted from the date of issuance of purchase order via email. It shall be the responsibility of DDOs to monitor the activity of placing purchase order via email/online module.**
4. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them.
5. The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report along with the comments and details as under: -

PROFORMA FOR NON-SUPPLY REPORT

R.C. No.	Item No. & Name of Drug	Name of firm	S.O. No. with Date	Preference (L1/L2/L3)	Qty. not supplied	Risk Purchase/ penalty levied	Payment if pending	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.

6. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.
7. It will be ensured before placing order by the Direct Demanding Officer that necessary funds are available and **payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.**
8. Supply orders/Purchase order(s) will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.



9. No guarantee can be given as to the minimum quantity which will be drawn against this contract but the approved Pharmaceutical firm will supply quantity as may be ordered by the Direct Demanding Officers during the currency of the contract.
10. The approved Pharmaceutical firm will supply the items immediately on demand or latest within six weeks of placing of supply order throughout the period of contract.
11. Supply orders/Purchase orders against the contract will be accepted as long as these reach the approved Pharmaceutical firm on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.
12. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm to supply the item as per the specifications of the relevant rate contract.

SUPPLIES

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.
14. During transit approved Pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.
15. The prices approved are F.O.R. Destination per unit and are exclusive of GST except where indicated but inclusive of all charges for packing and forwarding.
16. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.
17. **The approved Pharmaceutical firm will have to supply drugs directly in the quantity ordered, to ESIC or ESIS Institutions. The approved Pharmaceutical firm shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons. In case, at any stage of the contract, it is found that the approved Pharmaceutical firm has appointed the distributors/dealers/third party agent for making supply or receiving of supply order against the contract, ESI Corporation will initiate the following actions against the approved Pharmaceutical firm(s):**



- a. 100% forfeiture of Performance Security from the valid current all DG-ESIC Rate Contract(s).
- b. Blacklisting for participation in the future tender enquiries for all ESI Institutions for a period of two years prospectively.

18. Marking/Labelling:

Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

19. Packing:

- a) **It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted/rubber stamping with indelible ink clearly. Any consignment without such stamping will not be considered valid and will be rejected.**
- b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.
- c) Supplies to be made in proper boxes.
- d) *Liquid orals to be supplied only in glass/ plastic bottles conforming to Drugs & Cosmetics Act and rules made there under.*
- e) Large volume parenterals to be supplied only in plastic bottles / polypacks conforming to Drugs & Cosmetics Act and rules made there under.
- f) It should be ensured that only **first use packaging material of uniform size including Bottles and vials** should be used for making supplies on the basis of ESI Rate Contract.
- g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.
- h) Packing should be able to prevent damage or deterioration during transit.
- i) All containers i.e. bottle, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written on any labels otherwise it will be disqualified.
- j) All DGESIC approved pharmaceutical firm will make supply bearing Quick response code on its label at each level packaging that store data or information readable with software application to facilitate tracking and tracing as per Gazette Notification and CDSCO guidelines time to time (Where ever Applicable).



20. Life Period :

I:

- a) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
- b) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
- c) Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of valid shelf life from the date of manufacture.

II.

Notwithstanding the above, DDOs/Authorized nominated officer by DDO may relax this criteria in case of exigencies with reasons duly recorded and shall be responsible for use of that stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any financial loss to the Corporation.

21. Pharmacopoeia Specifications:

Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation supplied as per the provisions of Drug and Cosmetics Act.

22. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

23. It should be ensured that ISI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has ISI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards (Where ever Applicable).

24. Testing of Drugs – Quality Control

- a. Approved Rate Contract Holder should mandatorily submit a Test Report for that particular batch of medicines tested by the Government/Government approved Laboratories along with each supply, failing which supply received will be liable for rejection at the inspection stage and penalty of late supply will be levied as per provisions.
- b. Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.



- c. Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the approved Pharmaceutical firm/ firms at regular interval to maintain and ensure the quality of drugs.
- d. Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.
- e. The report of the Govt./Govt. approved laboratory shall be accepted by the approved Pharmaceutical firm. In case the same is disputed by the approved Pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However, the same should be submitted **within three months**, from the date of communication of the disputed test report to the approved Pharmaceutical firm. For this, the approved Pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory **at their own cost**. In case no response is received from the approved Pharmaceutical firm within the stipulated period, action as deemed fit as per terms & conditions of the Rate Contract will be initiated.
- f. For imported items: - The approved Pharmaceutical firm must submit the In-house test report of Principal manufacturer with each and every batch of supply.
- g. If any drug/s supplied against this Rate Contract are found to be "Not of Standard Quality" on inspection by Competent Authority, the approved Pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the approved Pharmaceutical firm/s.
- h. If the product is found to be "Not of Standard Quality", the cost of testing will be recovered from the approved Pharmaceutical firms and further action will be taken as per clause no. 25 mentioned below:
25. The classification of defects into different categories is as per the guidelines issued by the Drugs Controller General (India), Central Drugs Standard Control Organization (CDSCO) & action will be taken by ESIC for each category of defects, described as below: -
- A. CATEGORY 'A' DEFECT (Spurious / Adulterated Drugs)-**
- If any item / Batch of the item declared Not of Standard quality (NSQ) under Category A .**
- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Recoveries to be initiated by the DDO's wherever payment had been made already.
 - **100% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for all the quoted drugs.

- Debarring of the Rate Contract holder /approved Pharmaceutical firm from current and all future DGESIC Rate Contract for participation in tender enquiry of all ESIC institutions prospectively for a period of two years.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs):

1. If single item/ Batch of item is declared NSQ under Category B:

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **20% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for that drug as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item.
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

a) If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category B

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **50% (20% + 30%) Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- **Any subsequent (3rd onwards) NSQ reported** of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current and all future DGESIC Rate Contracts for a period of two years for participation in all ESI Institutions prospectively along with forfeiture of **100% performance security for all NSQ declared items.**



- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
- b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category B within a year**
- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **100% Forfeiture of Performance Security from the respective DGSIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.**
- Debarring of Rate Contract Holder/approved Pharmaceutical firm immediately from current and all future DGSIC Rate Contracts for the item for a period of two years for participation in all ESI Institution prospectively.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

C. CATEGORY ' C' DEFECT (Minor Defects)

1.If single item/ Batch of item is declared NSQ under Category C

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

a)If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category-C.

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Warning to be issued to the firm for the NSQ item.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category C within a year.



- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **10% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.
- **Any subsequent (2nd NSQ onwards) NSQ** reported of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current DGESIC Rate Contracts.
- Warning to be issued to the firm for the NSQ item
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

26. **Delivery Period – Risk Purchase**

- a. Delivery period will be of six weeks from the date of **issuance of purchase order via email** and the approved Pharmaceutical firm shall execute the order within stipulated time.
- b. If the approved Pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) percent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. An approved Pharmaceutical firm can seek extension of the delivery period with the prior consent of the Direct Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. The extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned DDO.
- c. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other approved Pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate or from local chemist. All DDOs of ESIC & ESIS Institutions shall record each instance of Non-Supply of respective approved Pharmaceutical Firm and a consolidated quarterly non-supply report to be submitted at ESIC HQRS.

Extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.

- d. i) If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of approved Pharmaceutical firm. **The**



extra expenditure involved in procuring supplies from elsewhere i.e. L2 firm/other running Govt. Contract/ Local Purchase etc. will be recoverable from the approved Non-supplying Pharmaceutical firm, in full by Direct Demanding Officers.

ii) The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with bidder by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the bidder's Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than two years.

- e. If the approved Pharmaceutical firm fails to execute the supply order three times at any location of ESIC & ESIS in any part of the country during the period of rate contract, it shall be debarred for the next two years with effect from the last failure and forfeiting of Performance Security for that drug.

27. Payment

Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm/bidder to supply the items as per the specifications of the relevant rate contract. No claim for the payment from contractor shall be entertained after the lapse of three years of arising of the claim.

28. Any dues or payments that have arisen to the Corporation from the approved Pharmaceutical firm for which no specific time limit has been laid down in the terms and conditions shall be payable by the approved Pharmaceutical firm within such time limit as may be prescribed in the letters/orders addressed to the approved Pharmaceutical firms.
29. Any payments that have been demanded as per the provisions of above-mentioned clause or under any other clause shall be payable within the time laid down. On failure to do so:
- The approved Pharmaceutical firm shall be liable to be debarred for supplying items/ drugs etc. to the Corporation for a period not exceeding two years.
 - The Corporation reserves its right to take appropriate legal action against the defaulting firms as may be legally advised, including claim for compensation and damages for the period of delay and / or simple interest 10% per annum for each day of default.
30. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed: -



(a) Items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.

(b) In case of items, where two approved Pharmaceutical Firms exist at L-1(1st Preference), it is mandatory for all Direct Demanding Officers (DDOs) to place Supply Orders in the ratio of 50% of the order quantity to each L-1 approved Pharmaceutical firm on each instance of placing of supply order. Same principal applies to L2 Firm (in case order is required to be placed with L2).

(c) For item No. **1070 & 1521** in **RC-166**, L-2 firms are Class-I Local Suppliers & have agreed to match the price of L-1 bidder. Therefore 50% of the order quantity to each L-1 approved Pharmaceutical firm to be placed on each instance of placing of supply order.

31. No other document should be entertained for giving any cognizance for placing the supply orders.
32. The validity of the contract of approved Pharmaceutical firm holding Patent right of approved drug/s in the currency of Rate Contract shall be for two years or till date of expiry of patent whichever is earlier. It is the sole responsibility of the patent holding firm to mandatorily inform ESIC Ten days before the expiry of the Patent of the approved drug/s in Rate Contract, failing which the participating firm shall be blacklisted in the participating and prospective RCs for a period of two years along with forfeiture of EMD/ Performance security (as the case may be) as per Terms & Conditions of the Tender Enquiries.
33. The Letter of Award issued to the firms by this office cannot be used for placing orders.
34. Standing Committee on Government e-Market (SCoGeM), Ministry of Labour & Employment has granted exemption to publish and operate DG-ESIC Rate Contract for the Drugs other than drugs reserved for CPSUs.
35. Force Majeure:
If at any time during the applicability of Contract the bidder fails to discharge its Obligation due to force majeure (natural disaster or act of God etc.) he will promptly notify the Director General or its representative about the happening of such an event. The Director General or its representative is solely entitled to terminate/ determine the order/contract in respect of such performance of the bidder(s) obligations if he so desires. The obligations under the contract on behalf of bidder for the contract shall be resumed as soon as practicable after the event has come to an end or ceased to exist.
36. It shall be the sole responsibility of Medical Superintendents/Deans/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO/ Head of Institutions of respective State to maintain



an optimum Inventory level with strict control as per ABC-VED matrix and ensure the drug formulary of the respective institution is followed in right earnest to provide medical services to ESI Beneficiaries.

37. All Deans/MSs/DIMS/Head of ESIC & ESIS Institutions are requested to keep a vigilant check on procurement of drugs (strictly monitor Re-Order Level, Buffer Stock, Lead Time etc.) in order to avoid obsolescence/expiry/excessive procurement of drugs resulting in infructuous expenditure.


This issue with the approval of Competent Authority.

Encl.: As above.

Copy to:

1. PPS/PS to Director General, ESIC for information.
2. PPS/PS to Finance Commissioner for information.
3. PPS/PS to Medical Commissioner (Procurement/ Medical Administration) for information.
4. Accounts Branch – V (Hqrs. Office)
5. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.
6. Website Content Manager for uploading on ESIC HQRS Website.
7. Guard File.

Yours faithfully,



(Dr. Sanjiv Kochhar)
Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL

डॉ. संजीव कोचर / Dr. Sanjiv Kochhar
उप विद्विता आयुक्त / Deputy Medical Commissioner
क.रा.बी.नि.(दु.) / E.S.I.C. (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02
Panchdeep Bhawan, C.I.G. Road, New Delhi-02



(Dr. Sanjiv Kochhar)
Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL

डॉ. संजीव कोचर / Dr. Sanjiv Kochhar
उप विद्विता आयुक्त / Deputy Medical Commissioner
क.रा.बी.नि.(दु.) / E.S.I.C. (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02
Panchdeep Bhawan, C.I.G. Road, New Delhi-02



List of Approved Pharmaceutical firms of Rate Contract No. 166

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
1.	166	Abbott Healthcare Pvt Ltd	3 Corporate Park, Sion Trombay Road, Chembur Mumbai 400071	(91-22) 38160527, (91-22) 38162401, 9833941108, institution.ahpl@abbott.com
2.	166	Abbott India Limited	3 Corporate Park, Sion Trombay Road, Chembur Mumbai 400071	(91-22) 38160527, (91-22) 38162401, 8076637791, institution.business@abbott.com
3.	166	Ajanta Pharma Ltd.	Ajanta House, 98/Govt. Industrial Estate, Charkop, Kandivali (West), Mumbai - 400 067	022 66061202/66061221, 022 66061200, 9821838599, dilip.bagdiya@ajantapharma.com
4.	166	ALPA LABORATORIES LTD	33/2, A.B. Road, Pigdamber 453 446, Indore (MP)	0731 4294567, -, 7415794617, tenders@alpalabs.in
5.	166	Aristo Pharmaceuticals Private Ltd.	29, DLF, Industrial Area Kirti nagar New Delhi-110015	011-25926403/04, NA, NA, delhi.br@aristopharma.co.in
6.	166	Bal Pharma Ltd	Bal Pharma Ltd, 5th Floor, Lakshminarayan Complex, Palace Road, Bangalore	080-41379527, 080-22354057, 9480811168, rajesh@balpharma.com, institution alsales@balpharma.com
7.	166	Bayer Pharmaceuticals Private Limited	Bayer House, Central Avenue, Hiranandani Estate, Thane (W) - 400607	022 2531 1234, 022 2545 5063, 9811694231, yogesh.prakash@bayer.com
8.	166	BDR Pharmaceuticals International Private Limited	Registered office at : 407/408, Sharda Chambers, 15 New Marine Lines, Mumbai 400020 (Maharashtra) Admn. : Engineering Centre, 6th Floor, 9 Matthew Road, Opera House, Charni Road. Mumbai - 400004	022-40560560, 022-40560555, +91-9811383631; +91-9136003333, manoj.kapoor@bdrpharma.com, tender@bdrpharma.com
9.	166	Biodeal Pharmaceuticals Ltd.	Vill. Saini Majra, Nalagarh Ropar Road Nalagarh, Himachal Pradesh 174101	0120-6025048, 0120-6025048, 7428744221, institution1@biodealpharma.com, Institution@biodealpharma.com
10.	166	Centaur Pharmaceuticals Pvt. Ltd.	Centaur House, A- Wing , Institutions Dept., Shanti Nagar, Vakola, Santacruz East Mumbai -400055	022-66499270/274, 022-66499112, 98202244293 / 9930593597, institutions@centaurilab.com, same er@centaurilab.com
11.	166	Cipla Ltd.	Cipla House Peninsula Business Park, Ganpatrao Kadam Marg, lower Parel, Mumbai- 400 013	022 24826000, 022 24826120, +91 9820273567 \ +91 9506692389,



ए. ए. सी. ई.
E S I C

List of Approved Pharmaceutical firms of Rate Contract No. 166

				Institution@Cipla.com,vishwas.ah uja@cipla.com,prashant.gupta1@ cipla.com,praveen.kumar18@cipla .com
12.	166	GALPHA LABORATORIES LIMITED	E 221, Kanakia Zillion Junction of LBS Marg and CST Road, BKC Annexe, Kurla West, Mumbai – 400070	22 3040 0999, 22 3040 0900, 7718883168, kuldeep.malhotra@galphi.com, arindam@galphi.com, sanjay.pathak@galphi.com
13.	166	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Limited, Glenmark House, B.D.Sawant Marg, Chakala, Andheri East, Mumbai - 400099	022-40189999, 022-40189986, 9867027126, govt.tenders@glenmarkpharma.c om
14.	166	HAB Pharmaceuticals & Research Ltd	A-301 PENINSULA BUSINESS PARK, GANPATRAO KADAM MARG LOWER PAREL MUMBAI 400013	022-66261409, 022-66261414, 9930212908, marketing@habpharma.in,instituti on@habpharma.in
15.	166	Healer's Lab	Avanbai Mansions, 3- Vidhan Sabha Marg, Lucknow-226001 U.P.	0522-2620365, N.A., 8795838376, institution.healerslab@gmail.com
16.	166	Hindustan Laboratories Limited	A-302, Victory Park, Chandavarkar Road, Borivali (West), Mumbai - 400092, Maharashtra	022-42460500, 42460526, 022- 42460531, 7710055194, sales@hindlab.com,tender@hindl ab.com,kunjaldedhia@hindlab.co m
17.	166	Indoco Remedies Ltd.	Indoco Remedies Limited, Indoco House, 166, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.	022 - 6287 1000/ 6817 1250, 022 - 2652 0884, 9004046733, mshetty@indoco.com, kiran.borle@indoco.com
18.	166	Intas Pharmaceuticals Ltd.	Intas Pharmaceuticals Limited, Corporate House, Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad- 380054	079-39837000, -, 9810824433, abhishek_bajaj@intaspharma.com
19.	166	Ipca Laboratories Ltd.	Plot No. 48, Kandivali Industrial Estate, Kandivali West, Mumbai - 400 067	022 - 6857 2895, NA, 9870130466, sandesh.prabhu@ipca.com,dinesh .shukla@ipca.com
20.	166	J B Chemicals & Pharmaceuticals Ltd	Neelam Centre, B Wing, 4th floor, Hind Cycle Road, Worli, Mumbai:400030	22 2439 5200/ 2439 5500, 22 2431 5331 / 2431 5334, 9987863378, sajida.khan@jbpharma.com,anan d.prasad@jbpharma.com
21.	166	LOGOS PHARMA	182/2, 3rd floor, Industrial area, Phase 1, Chandigarh- 160002	0172-4822400, NA, 6284300825, logos.tenders@gmail.com
22.	166	LUPIN LIMITED	3rd Floor, Kalpataru Inspire, Off Western Express Highway,	(022) 66402969, (022) 66402969, 8879967909,

f



List of Approved Pharmaceutical firms of Rate Contract No. 166

			Santacruz (East) , Mumbai - 400055	manoj Singh4@lupin.com
23.	166	MAAN PHARMACEUTICALS LTD.	MAAN PHARMACEUTICALS LTD., PLOT NO.1, G.I.D.C PHASE-2, MODHERA ROAD, MEHSANA-384 002	02762-224642, 02762 224610, 9825070124, info@maanpharma.com
24.	166	Macleods Pharmaceuticals Limited	Atlanta Arcade, Marol Church Road, Opposite Leela Hotel , Andheri (East), Mumbai – 400059	2266762672, 2229256599, 7304564056, tenders@macleodspharma.com
25.	166	MANKIND PHARMA LIMITED	M/s. Mankind Pharma Limited, 208, Okhla Industrial Estate, Phase-3, New Delhi-110020	011-46541400, 011-46541382, 9599911736 , 9873661749, tender@mankindpharma.com, rajesh.kaul@mankindpharma.com, garav.saxena@mankindpharma.com
26.	166	MASCOT HEALTH SERIES PVT LTD	B-1/635, 2nd Floor, Near Janakpuri East Metro Station, Janakpuri, New Delhi 110058	011-28542407/08/10, 0, 8800220714, gmsales.mkt@mascothealth.com, rkc.mascothealth@gmail.com
27.	166	MDC PHARMACEUTICALS LIMITED	PLOT NO. 46, INDUSTRIAL AREA, PHASE 2, CHANDIGARH 160002	0, NOT AVAILABLE, 9115516378, esisupplies@mdcpharmaceutical.com, legal@mdcpharmaceutical.com, singlamdc@gmail.com
28.	166	Med Manor Organics Pvt. Ltd.	16-11-477/45, Sri Krishna Niyam, Dilsukh Nagar, Hyderabad - 500036	040-24053155 & 32934530, 040 - 24041284, 8898880276, yogendra.mishra@medmanor.in, anesh.jayaraman@medmanor.in, esic@medmanor.in
29.	166	MESMER PHARMACEUTICALS	Mesmer Pharmaceuticals, Vedha No 13, Mangala Nagar, 1st Main Road, Porur, Chennai-600116, Tamil Nadu.	044-22522618, 0, 9444903427, tenders.mesmer@iconlife.in, gvsm ani.mesmer@iconlife.in
30.	166	MICRO LABS LTD	No. 31, Race Course Road, Bangalore-560 001	: +91-80-2237 0451-57 line, : +91-80-2237 0463 , 9350808984 ; 9591211411, rakeshsharma_micro@yahoo.co.in
31.	166	MICRON PHARMACEUTICALS	Plot No. 2117, A-2, Phase III GIDC Vapi 396 195	0260 2405400/405/407/412, 0260 2405419, 9924170750, sales@micronpharma.in, contactus @micronpharma.in, sales@micronpharma.in
32.	166	Midas Care Pharmaceuticals Pvt. Ltd.	Lotus Corporate Park, B Wing, 3rd Floor, Jay Coach, Graham Firth Compound, WE Highway, Goregaon (East), Mumbai 400 063	42193900, NA, 9013490294, tender@midas-care.com, sumitkumar.nagar@midas-care.com
33.	166	MODI	1400, MODI TOWER, 98,	011 4250 4992, 4555, 011 4250



List of Approved Pharmaceutical firms of Rate Contract No. 166

		MUNDIPHARMA PVT LTD	NEHRU PLACE , NEW DELHI 110019	2645 1659, 9990432604, pmd@modimundipharma.com,ne eraj.dhalla@modimundipharma.co m,tenders@modimundipharma.co m
34.	166	Morepen Laboratories Limited	2nd Floor, Tower - C, DLF Cyber Park, Udyog Vihar - III, Sector - 20, Gurugram - 122016 (Haryana)	0124 - 4892000, 0124 - 4892000, 9891759817, yadvinder.singh@morepen.com,in stitution@morepen.com
35.	166	Novo Nordisk India Private limited	NXT-2, 1 & 2nd Floor, Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli, Bangalore - 560045	8040303200, 8041123518, 9934300408, institutionsales@novonordisk.com ,surj@novonordisk.com
36.	166	Primus Pharmaceuticals	Primus Pharmaceuticals, Sadhoura Road, Mouza Ogli Khari, Vill. Asgarpur Majra, Distt. Sirmour ,173030, H.P	0, 0, 9034004055 and 7056797055, tenders@primuspharmaceutical.c om,marketing@primuspharmaceu tical.com
37.	166	Pulse Pharmaceuticals Pvt Ltd	Pulse Pharmaceuticals Pvt Ltd., Plot No: 18/1, Sector III, HUDA Techno Enclave, Hitech City-Hyderabad - 500 081.	91-40-23119992, 91-40- 23119992, 9346155755, 9311083087, suresh@pulsepharma.net,dineshk umar@pulsepharma.net
38.	166	Reliance Life Sciences Pvt. Ltd.	R-282, TTC Area of MIDC, Thane Belapur Road, Navi Mumbai-400701	,+91-22-35338000, ,+91- 2235338099, 8591404088, mahesh.kumar@relbio.com
39.	166	RIVPRA FORMULATION PVT. LTD,	RIVPRA FORMULATION PVT. LTD. CORPORATE OFFICE: RADISSON BLU, KM TRADE TOWER, 11TH FLOOR, OFFICE NO: 1008, H-3, KAUSHAMBI, GHAZIABAD-201010 (U.P)	(0120-4277177), 0120-4277177, 9999811834, 8800394441, tender@rivpraformulation.com,inf o@rivpraformulation.com
40.	166	RPG Life Sciences Ltd	RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030	022 2 4981650 / 67555276(D), 022 2 4970127 , 7738238787, smita.bhoir@rpgls.com
41.	166	Servier India Private Limited	1703, 17th Floor, Crescenzo Business District, 'B' Wing, Plot Nos. C 38 & 39, "G" Block, Behind MCA, Bandra Kurla Complex, Bandra (East), Mumbai - 400051.	022 - 68100700, -, -, servier.sales@servier.com,m.guru lingam@servier.com
42.	166	Signature Phytochemical Industries	Signature Phytochemical Indutries, A-301 Peninsula Business Park Ganpatrao Kadam Marg Lower parel Mumbai 400013	022-66261400, 022-6624141, 8976716569, marketing@signaturepi.in
43.	166	STADMED PRIVATE	"KUMUD", 14A, MONOHARPUKUR ROAD,	033 2474 0650, 033 2474 0643, 9088464665, roy@stadmed.co.in



List of Approved Pharmaceutical firms of Rate Contract No. 166

		LIMITED	KOLKATA 700026 (WEST BENGAL)	
44.	166	T.Walker's Pharmaceuticals Pvt Ltd	Gat No 285- A Plot No 10 +11 Village Kasaramboli At post Ambedvet Tal Mulshi Dist. Pune Maharashtra Pin:412108	NA, NA, 9371009400/9822675123 t.walkers1916@gmail.com,abhijee t.kudalkar@twalkerspharma.com
45.	166	Tablets (India) Limited	# 72, Marshalls Road, " Jhaver Centre" R A Building, 4th Floor, Egmore, Chennai, 600 008	044 - 4205 0000, 044 - 2858 9090, --, hd@tabletsindia.com
46.	166	Theon Pharmaceuticals Limited	Plot no. 400, Industrial Area, Phase-1, Panchkula-134113	0172-5210200, 0172-5033851, 7696000688, tender@theonpharma.com,spsing h@theonpharma.com
47.	166	Torrent Pharmaceuticals Ltd,Ahmedabad	Torrent Pharmaceuticals LTd, Torrent House, Off Ashram Road, Ahmedabad-380009	079 26599551, , 079 26582100, 7069000550 , 578 , 509 , 559, hemantameher@torrentpharma.com,vikrampatel@torrentpharma.com,jaydabhi@torrentpharma.com ,bijendrakumarsharma@torrentia n.com,hadmatkhatik@torrentphar ma.com,ISDORDERS@TorrentPha rma.com
48.	166	Troikaa Pharmaceuticals Limited	Troikaa House - 1, Satya Marg, Bodakdev, Ahmedabad - 380054	079 26856242, 079 26856246, 7227069020, tenderorder@troikaapharma.com, head_inst@troikaapharma.com
49.	166	ULTRA DRUGS PVT. LTD.	Corporate/Correspondence office: H.NO. 436, VILLAGE SAKETRI, DISTT. PANCHKULA-134109 (H.R.) Regd. Office: H.NO. 1201, SECTOR-22B CHANDIGARH-160022	0195-236918-20, 01795-236917, 78078 87915, manoj.tenders@ultradrgs.co.in,d irector@ultradrgs.co.in
50.	166	UNICURE INDIA LTD	C-21, 22 & 23, Sector-3, Noida-201301, distt. Gautam Budh Nagar (U.P.)	0120-4786713, 0120-4320184, 9810337912, unicure@unicureindia.com,mkum ar712@gmail.com
51.	166	USV Private Limited	USV Private Limited, Arvind Vithhal Gandhi Chowk, B.S.D marg, Govandi Station Road, Govandi - East, Mumbai - 400088	022 - 2556 4048, 022 - 2558 4025, 9871594946, manoj.sharma@usv.in
52.	166	Wallace Pharmaceuticals Pvt. Ltd.	Wallace Towers, 5th Floor, Navpada, Bahar Cinema, off WE Highway, Vile Parle(East), Mumbai-400057	022-68311133, 022-28390733, 9820360019 / 9811129701, pravinwani@wallacepharma.net,in stitution@wallacepharma.net,prav inwani@wallacepharma.net,institu tion@wallacepharma.net,ms379@



List of Approved Pharmaceutical firms of Rate Contract No. 166

				hotmail.com
53.	166	Windlas Biotech Limited	705-706, Vatika Professional point, sector-66 golf course ext, road, Gurgaon-122001 Haryana	124-2821030, 124-2821060, 9555823672, institutionalhead@windlasbiotech.com
54.	166	Wings Biotech LLP	J-13, Udyog Nagar Industrial Area, Near Peeragarhi Metro Station, Delhi- 110041	011-45922222, NA, 9871112877, manager.govtsupply@wingsbiotech.com, institution.exe@wingsbiotech.com, wingstender.co@gmail.com
55.	166	ZIM LABORATORIES LIMITED	Saddoday Gyan (Ground Floor), Opp. NADT Nelson Square, Nagpur-440013 (MS)	7122981960, 7118271470, 9818678219, tendercell@zimlab.in, admin01@zimlab.in, marketing@zimlab.in
56.	166	Zuventus Healthcare Limited	Zuventus House, Plot Y2, CTS NO: 358/A2, Near Nahur Railway Station, Nahur (West), Mumbai- 400078	022 35060000, 022 20812898, 9054797511, Rajiv.Kumar@zuventus.com, sheetal.khanvilkar@zuventus.com
57.	166	Zydus Healthcare Limited	M/s. Zydus Healthcare Limited Zydus Tower, CTS No. 460/6, Village Pahadi, Opposite IB Patel Road, Goregaon E, Mumbai – 400063	91-22-62721700, 91-22-62721700, 9957194623, institutionsales@zyduslife.com

क.रा.बी.नि.
ESIC



Index RC- 166

S.No.	RC No.	Item No.	Item Name and Description
1.	166	36	Bromhexine Syp - Each 5ml to contain: Bromhexine Hcl. 4mg., 100ml Bottle
2.	166	48	Iso-Sorbide Dinitrate Tab/Cap- Each Tab/Cap to contain: Iso-Sorbide Dinitrate 10mg
3.	166	93	Diazepam Inj-Each ml to contain: Diazepam 5mg, 2mlAmp
4.	166	99	Carbamazepine Tab/Cap- Each Tab/Cap to contain: Carbamazepine 200mg
5.	166	363	Theophyllin CR Tab/Cap-Each CR Tab/Cap to contain: Theophyllin Anhydrous 400 mg
6.	166	1033	Etophylline & Theophylline SR Tab/Cap-Each SR Tab/Cap to contain: Etophylline 231mg, Theophylline 69mg
7.	166	1039	Salbutamol Inhaler- Each metered dose to contain: Salbutamol 100 mcg. (Equal to or more than 120MDI)
8.	166	1070	Frusemide+Spironolactone Tab/Cap-Each Tab/Cap to contain: Frusemide 20 mg, Spironolactone 50 mg.
9.	166	1071	Acetazolamide Tab/Cap-Each Tab/Cap to contain: Acetazolamide 250 mg
10.	166	1072	Cinnarizine Tab/Cap - Each Tab/Cap to contain: Cinnarizine 25mg.
11.	166	1120	Lithium Carbonate 450 mg CR Tab
12.	166	1130	Phenytoin Inj- Each ml to contain: Phenytoin Sod. 50 mg,2ml Amp
13.	166	1392	Oxcarbazepine Tab/Cap- Each Tab/Cap to contain: Oxcarbazepine 150mg
14.	166	1451	Human Coagulation Factor IX 600 IU Freeze Dried
15.	166	1458	Amiodarone Tab/Cap - Each Tab/Cap to contain: Amiodarone 200mg
16.	166	1512	Ambroxol Hcl +N-Acetyl-L-Cysteine Tab/Cap - Each Tab/Cap to contain:Ambroxol Hydrochloride 30 mg, N - Acetyl - L - Cysteine 200 mg,
17.	166	1513	Montelukast + Levocetirizine Tab/Cap - Each Tab/Cap to contain: Montelukast 10mg, Levocetirizine Dihydrochloride 5mg.
18.	166	1520	Inhaler -



S.No.	RC No.	Item No.	Item Name and Description
			Each Inhaler to contain: Moulded Plastic Device Containing A Foil Strip With 30/ 60 Regularly Placed Blisters Each Containing 50 Mcg Of Salmeterol Xinafoate And 250 Mcg Of Fluticasone Propionate
19.	166	1521	Inhaler - Each metered dose to contain: Tiotropium Bromide Monohydrate Equ. To Tiotropium 9mcg (equal to or more than 120 MDI)
20.	166	1526	Ipratropium+ Levosalbutamol Resp -Each 2.5ml/3.0ml Respules to contain : Ipratropium I.P.500mcg, Levosalbutamol 1.25mg.
21.	166	1532	Isosorbide Dinitrate Tab/Cap- Each Tab/Cap to contain: Isosorbide Dinitrate 5mg
22.	166	1573	Piracetam Tab/Cap - Each Tab/Cap to contain: Piracetam 400mg.
23.	166	1575	Pregabalin + Methylcobalamin Tab/Cap Each Tab/cap. to contain: Pregabalin 75 mg, Methylcobalamin 750 mcg.
24.	166	1576	Gabapentine +Mehylcobalamin Tab/Cap Each Tab/cap. to contain: Gabapentine 300 mg, Methylcobalamin 500mcg.
25.	166	1664	Cough Syrup : Each 100ml solution to contain: Dried Ivy leaf extract 0.7gm, 100ml Bottle
26.	166	1665	Inhaler - Each metered dose to contain : Tiotropium 9mcg, Formoterol 6 mcg, Ciclesonide 200mcg (CFC Free)(equal to or more than 120 MDI)
27.	166	1671	Acenocoumarol Tab/Cap - Each Tab/Cap to contain: Acenocoumarol 4mg
28.	166	1745	Doxofylline Tab/Cap - Each Tab/Cap to contain: Doxofylline 400mg
29.	166	1746	Omalizumab Inj -Each vial to contain: Omalizumab 150mg
30.	166	1753	Telmisartan, Amlodipine Tab/Cap - Each Tab/Cap to contain: Telmisartan 40 mg, Amlodipine Besylate equivalent to Amlodipine 5 mg .
31.	166	1839	Autohaler- Each Deliver Dose Of Autohaler/Syncobreath to contain: Formoterol Fumarate Dihydrate IP 6 mcg, Budesonide IP

ए. ए. ई. सी.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
			200 mcg Equal to or more than 120 MDI
32.	166	1846	Propranolol Tab/Cap- Each Tab/Cap to contain: Propranolol 10mg
33.	166	1850	Labetalol Tab/Cap - Each Tab/Cap to contain: Labetalol 100mg
34.	166	1851	Moxonidine Tab/Cap- Each Tab/Cap to contain: Moxonidine 0.2mg
35.	166	1852	Cilnidipine Tab/Cap - Each Tab/Cap to contain: Cilnidipine 10 mg
36.	166	1854	Cilostazol Tab/Cap- Each Tab/Cap to contain: Cilostazol 100mg
37.	166	1882	Lamotrigine Dispersible Tab/Cap- Each Disp Tab/Cap to contain: Lamotrigine 25mg
38.	166	1885	Levetiracetam Inj-Each ml to contain : Levetiracetam100 mg,5ml Vial/Amp
39.	166	2016	Budesonide 200mcg + Formoterol Fumarate 6mcg Rotocap- Each Rotacap to contain: Budesonide 200mcg + Formoterol Fumarate 6mcg
40.	166	2026	N-Acetyl Cysteine Tab/Cap- Each Tab/Cap to contain: N-Acetylcysteine 600mg
41.	166	2062	Indacaterol + Glycopyrronium Tab/Cap- EachTab/Captocontain:143mcgIndacaterolMaleateEqv.to110 mcgIndacaterol&63mcgGlycopyrroniumBromide Eqv to 50 mcg Glycopyrronium.
42.	166	2212	Epleronone Tab/Cap-EachFilmCoatedTab/Cap to contain:Epleronone 25mg
43.	166	2213	Clonidine Tab/Cap- Each Tab/Cap to contain: Clonidine 0.1 mg
44.	166	2214	Memantine Hcl 10 mg Tab
45.	166	2301	Carvedilol Phosphate 10 mg CR Tab
46.	166	2304	Acetyl Salicylic Acid + Clopidigrel Tab/Cap- Each Tab/Cap to contain: Acetyl Salicylic Acid 75mg, Clopidigrel 75mg
47.	166	2305	Trimetazidine Tab/Cap-



S.No.	RC No.	Item No.	Item Name and Description
			Each PLAIN/SR/CR/DR/ER/MR Tab/Cap to contain: Trimetazidine 60mg
48.	166	2308	Chlorthalidone 6.25mg
49.	166	2310	AMINOPHYLLINE INJECTION IP 10 ML AMPOULE:AMINOPHYLLINE IP (25 mg) Water for Injection IP (Q. S. TO 1.0 ml)
50.	166	2313	Venlafaxine CR/ SR/ DR/ MR Tab/Cap- Each CR/ SR/ DR/ MR Tab/Cap to contain: Venlafaxine 37.5mg
51.	166	2428	Donepezil Hcl 10 mg Tab
52.	166	2430	Levetiracetam Syp- Each ml to contain: Levetiracetam 100mg,100ml Bottle
53.	166	2431	Etizolam Tab/Cap- Each Tab/Cap contain: Etizolam 0.5mg
54.	166	2432	Sodium Valproate 100 mg/ml
55.	166	2435	Warfarin Sodium Tab/Cap- Each Tab/Cap contain: Warfarin Sodium 3mg
56.	166	2436	Warfarin Sodium Tab/Cap- Each Tab/Cap contain: Warfarin Sodium 2mg
57.	166	2439	Telmisartan+Hydrochlorothiazide Tab/Cap- Each Tab/Cap contain: Telmisartan 40mg + Hydrochlorothiazide 12.5mg
58.	166	2440	Prasugrel Tab/Cap- Each Tab/Cap contain: Prasugel 5mg
59.	166	2441	Rivaroxaban Tab/Cap- Each Tab/Cap contain: Rivaroxaban 10mg
60.	166	2442	Topiramate Tab/Cap-Each Tab/Cap contain: Topiramate 50mg
61.	166	2444	Pramipexole Dihydrochloride Tab/Cap- EachTab/Capcontain:PramipexoleDihydrochloride1mg
62.	166	2450	Budesonide Respule- Each Respule to contain:Budesonide 0.5mg
63.	166	2451	Diltiazem Hydrochloride Gel- Each Tube to contain: Diltiazem Hydrochloride 2%
64.	166	2569	Acebrophylline Tab/Cap: Each tab/cap to contain

भ.स.वि.वि.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
			Acebrophylline 200mg
65.	166	2570	Acebrophylline+Acetylcysteine Tab/Cap: Each tab/cap to contain Acebrophylline 100mg+Acetylcysteine 600mg
66.	166	2573	Ambroxol Hydrochloride Respules :Each 2 ml Respule contain: Ambroxol Hydrochloride 15mg.
67.	166	2575	Amisulpride Tab/Cap :Each Tab/cap to contain Amisulpride 100 mg.
68.	166	2577	Aripiprazole 10 mg Tab
69.	166	2578	Atomoxetine Hcl 10 mg Tab
70.	166	2579	Atorvastatin + Fenofibrate -Each Tab/Cap to contain:Atorvastatin 10mg+ Fenofibrate 160mg
71.	166	2582	Bisoprolol Tab/Cap: Each Tab/cap to contain Bisoprolol 2.5 mg
72.	166	2585	Chlordiazepoxide tab/cap:Each Tab/cap to contain Chlordiazepoxide 10mg
73.	166	2586	Chlordiazepoxide tab/cap:Each Tab/cap to contain Chlordiazepoxide 25mg
74.	166	2587	Clonazepam+Escitalopram tab/cap:Each Tab/cap to contain Clonazepam (0.5mg) + Escitalopram(10mg).
75.	166	2590	Donepezil Hcl 5 mg + Memantine Hcl 5 mg Tab
76.	166	2591	Melatonin Spray: Each 0.2 ml liquid contains Melatonin 0.3 MG ,12ml Bottle
77.	166	2592	Glycopyrrolate + Formoterol Multidose Inhaler: Glycopyrrolate I.P. 9.0 mcg, Formoterol Fumarate Dihydrate I.P. eq. to Formoterol Fumarate 4.8 mcg, 120 MDI
78.	166	2593	Mometasone+Glycopyrronium+Indacaterol capsule: Each capsule contains : Mometasone Furoate eq. to 136 mcg of Mometasone Furoate IP 160 mcg, Glycopyrronium Bromide eq. to 46 mcg of Glycopyrronium Ph. Eur 63 mcg, Indacaterol Acetate eq. to 114 mcg of Indacaterol IH 173 mcg inhalation powder
79.	166	2594	Vilanterol+Fluticasone+Glycopyrronium capsules: Each capsule contains: Vilanterol Trifenatate eq. to Vilanterol 25 mcg, Fluticasone Furoate 100 mcg, Glycopyrronium Bromide Ph. Eur eq. to Glycopyrronium 50 mcg, excipients q.s.
80.	166	2595	Metoprolol+ Amlodipine+Telmisartan: Each film coated



S.No.	RC No.	Item No.	Item Name and Description
			bilayered tablet contains: Metoprolol Succinate IP 47.50 mg equivalent to Metoprolol Tartrate 50 mg (As extended release) Amlodipine Besilate IP equivalent to Amlodipine 5 mg, Telmisartan IP 40mg
81.	166	2596	Perindopril+Indapamide+Amlodipine Tab/Cap: Each Uncoated tablet contains Perindopril Erbumine IP 4MG Indapamide IP 1.25MG Amlodipine Besylate I.P. equivalent to Amlodipine 5mg
82.	166	2597	Perindopril+Amlodipine Tab/Cap:Each uncoated tablet contains perindopril Erbumine I.P. 4 mg+Amlodipine Besylate IP equivalent to Amlodipine 10mg
83.	166	2598	Efonidipine Hydrochloride Ethanolate tab/cap: Each Tab/cap to contain Efonidipine Hydrochloride Ethanolate 20mg
84.	166	2602	Fluvoxamine tab/cap: Each Tab/cap to contain Fluvoxamine 100 mg
85.	166	2603	Flupentixol tab/cap: Each Tab/cap to contain Flupentixol 1 mg
86.	166	2604	Flupentixol tab/cap: Each Tab/cap to contain Flupentixol 3 mg
87.	166	2606	Fluvoxamine tab/cap: Each Tab/cap to contain Fluvoxamine 50 mg
88.	166	2610	Isosorbide Di nitrate+Hydralazine tab/cap:Each Tab/cap to contain Iso sorbide DI nitrate 20mg + Hydralazine 37.5mg
89.	166	2612	Lacosamide Tab/Cap:Each Tab/Cap to contain Lacosamide 50mg
90.	166	2614	Levosulpiride tab/cap:Each Tab/cap contains Levosulpiride 25mg
91.	166	2623	METOLAZONE Tab/Cap:Each Tab/cap to contain METALAZONE 2.5mg
92.	166	2625	Taurine+Acetylcysteine Tab/Cap:Each Tab/Cap to contain Taurine (500mg) + Acetylcysteine (150mg)
93.	166	2626	NALTREXONE Tab/Cap:Each Tab/Cap to contain NALTREXONE 50mg
94.	166	2628	Nebivolol Tab/Cap:Each Tab/Cap to contain Nebivolol 2.5mg
95.	166	2633	Oxcarbazepine Tab/Cap:Each Tab/Cap to contain Oxcarbazepine 300mg



E S I C

S.No.	RC No.	Item No.	Item Name and Description
96.	166	2635	Quetiapine Fumarate 300 mg Tab
97.	166	2640	Telmisartan+Chlorthalidone Tab/Cap:Each Tab/Cap to contain Telmisartan 40mg + Chlorthalidone 12.5 mg
98.	166	2643	Anti Hemophilic Factor Concentrate VIII (r-DNA glycopegylated),500 IU vial with diluent
99.	166	2644	Anti Hemophilic Factor Concentrate VIII (r-DNA glycopegylated),1000 IU vial with diluent
100.	166	2645	Anti Hemophilic Factor Concentrate VIII (r-DNA glycopegylated),2000 IU vial with diluent
101.	166	2646	Vericiguat Tab:Each Tab to contain Vericiguat 2.5mg
102.	166	2647	Vericiguat Tab:Each Tab to contain Vericiguat 5mg
103.	166	2649	Zolpidem+Melatonin Tab/Cap:Each Tab/Cap to contain Zolpidem 5mg+ Melatonin 3mg
104.	166	2650	Zonisamide 100 mg Cap
105.	166	1043b	Rotahaler Device - Rotahaler
106.	166	1061a	GlycerylTrinitrateCRTab/Cap-EachCRTab/Captocontain : Glyceryl Trinitrate 2.6 mg.
107.	166	1127b	Carbamazepin CR Tab/Cap- Each CR Tab/Cap to contain : Carbamazepin 400 mg
108.	166	1533a	Hydrochlorothiazide Tab/Cap- Each Tab/Cap to contain: Hydrochlorothiazide 12.5mg
109.	166	1534a	Human Coagulation Factor VII Inj-Each vial to contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 1mg
110.	166	1534b	Human Coagulation Factor VII Inj-Each vial to contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 2mg
111.	166	1539a	Betahistine hydrochloride/ Dihydrochloride Tab/Cap- Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 8mg
112.	166	1539b	Betahistine hydrochloride/ Dihydrochloride Tab/Cap- Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 16mg



S.No.	RC No.	Item No.	Item Name and Description
113.	166	1540a	Rosuvastatin Tab/Cap - Each Tab/Cap to contain: Rosuvastatin 10mg
114.	166	1540b	Rosuvastatin Tab/Cap - Each Tab/Cap to contain: Rosuvastatin 20mg
115.	166	336a	Carvedilol Tab/Cap- Each Tab/Cap to contain: Carvedilol 3.125mg
116.	166	341a	Iso-Sorbide Mononitrate SR Tab/Cap - Each SR Tab/Cap to contain: Iso-sorbide Mononitrate 30mg.
117.	166	341b	Iso-Sorbide Mononitrate SR Tab/Cap - Each SR Tab/Cap to contain: Iso-sorbide Mononitrate 60mg.
118.	166	374b	Sertraline 50 mg Tab
119.	166	420b	Fluticasone + Salmeterol Inhaler - Each metered dose to contain: Salmeterol 25mcg. + Fluticasone 250mcg. (equal to or more than 120MDI)
120.	166	433a	Sodium Valproate + Valproic Acid CR Tab/Cap - Each CR Tab/Cap to contain: (Sodium Valproate + Valproic Acid) eqv. to Sodium Valproate 200mg.
121.	166	463a	Zolpidem Tab/Cap- Each Tab/Cap to contain: Zolpidem 5mg
122.	166	463b	Zolpidem Tab/Cap - Each Tab/Cap to contain: Zolpidem 10mg.
123.	166	470b	Perindopril Tab/Cap - Each Tab/Cap to contain: Perindopril 4mg
124.	166	472a	Clonazepam Tab/Cap -
125.	166	473b	Resperidone Tab/Cap- Each Tab/Cap to contain: Resperidone 2mg
126.	166	474a	Olanzapine Tab/Cap - Each Tab/Cap to contain: Olanzapine 2.5mg.
127.	166	52b	Nifedipine SR Tab/Cap- Each SR Tab/Cap to contain: Nifedipine 20mg
128.	166	56a	Enalapril Maleate 2.5 mg Tab
129.	166	56b	Enalapril Maleate Tab/Cap- Each Tab/Cap to contain: Enalapril Maleate 5mg
130.	166	61a	Spironolactone Tab/Cap -



क.स.बी.नि.
ESIC

S.No.	RC No.	Item No.	Item Name and Description
			Each Tab/Cap to contain: Spironolactone 25mg.
131.	166	68b	Ethamsylate tab/Cap- Each Tab/Cap to contain Ethamsylate 500 mg
132.	166	72a	Acenocoumarol Tab/Cap - Each Tab/Cap to contain: Acenocoumarol 1mg
133.	166	94a	Alprazolam Tab/Cap- Each Tab/Cap to contain: Alprazolam 0.25mg
134.	166	94b	Alprazolam Tab/Cap- Each Tab/Cap to contain: Alprazolam 0.5mg

(Handwritten signature)

क.स.बी.नि.
ESIC

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Morepen Laboratories Limited	36	Bromhexine Syp - Each 5ml to contain: Bromhexine Hcl. 4mg., 100ml Bottle	1ml	BROMIPEN	100ml Bottle	0.10/1ml	Paise Ten Only	L-1 (50% of Order Quantity)
166	GALPHA LABORATORIES LIMITED	36	Bromhexine Syp-Each 5ml to contain: Bromhexine Hcl. 4mg.,100ml Bottle	1ml	Brox Syrup	100 ml Bottle	0.10/1ml	Paise Ten Only	L-1 (50% of Order Quantity)
166	MICRON PHARMACEUTICALS	36	Bromhexine Syp-Each 5ml to contain: Bromhexine Hcl. 4mg.,100ml Bottle	1ml	Same as in Item	100ml Bottle	0.11/1ml	Paise Eleven Only	L-2
166	Hindustan Laboratories Limited	36	Bromhexine Syp -Each 5ml to contain: Bromhexine Hcl. 4mg., 100ml Bottle	1ml	HIBROME	100ml Bottle	0.17/1ml	Paise Seventeen Only	L-3
166	Abbott Healthcare Pvt Ltd	48	Iso-Sorbide Dinitrate Tab/Cap- Each Tab/Cap to contain: Iso-Sorbide Dinitrate 10mg	1 Tab/Cap	Sorbitrate 10	50 Tab	0.21/1 Tab	Paise Twenty One Only	L-1
166	Ipca Laboratories Ltd.	48	Iso-Sorbide Dinitrate Tab/Cap- Each Tab/Cap to contain: Iso-Sorbide Dinitrate 10mg	1 Tab/Cap	Isordil-10	10 Tab	0.40/1 Tab	Paise Forty Only	L-2
166	Intas Pharmaceuticals Ltd.	48	Iso-Sorbide Dinitrate Tab/Cap- Each Tab/Cap to contain: Iso-Sorbide Dinitrate 10mg	1 Tab/Cap	MONIT 10	15 Tab	1.60/1 Tab	Rupee One Paise Sixty Only	L-3
166	ALPA LABORATORIES LTD	93	Diazepam Inj-Each ml to contain: Diazepam 5mg, 2mlAmp	1 Vial/Amp	Same as in Item	2ml Amp	6.29/1 Amp	Rupees Six Paise Twenty Nine Only	L-1
166	Abbott Healthcare Pvt Ltd	99	Carbamazepine Tab/Cap- Each Tab/Cap to contain: Carbamazepine 200mg	1 Tab/Cap	Mazetol 200	10 Tab	1.09/1 Tab	Rupee One Paise Nine Only	L-1
166	Intas Pharmaceuticals Ltd.	99	Carbamazepine Tab/Cap- Each Tab/Cap to contain: Carbamazepine 200mg	1 Tab/Cap	ZEN-200	10 Tab	1.40/1 Tab	Rupee One Paise Forty Only	L-2

ESIC

[Handwritten Signature]
28 | Page

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	UNICURE INDIA LTD	363	Theophyllin CR Tab/Cap-Each CR Tab/Cap to contain: Theophyllin Anhydrous 400 mg	1 Tab/Cap	Same as in Item	10 Tab	6.99/1 Tab	Rupees Six Paise Ninety Nine Only	L-1
166	ZIM LABORATORIES LIMITED	1033	Etopylline & Theophylline SRTab/Cap-EachSRTab/Captocontain: Etopylline 231mg, Theophylline 69mg	1 Tab/Cap	ETHOLLINE SR	10 Tab	1.05/1 Tab	Rupee One Paise Five Only	L-1
166	Cipla Ltd.	1039	Salbutamol Inhaler - Each metered dose to contain: Salbutamol 100 mcg. (Equal to or more than 120MDI)	1 Dose	ASTHALIN INHALER	200 MD	0.26/1 MD	Paise Twenty Six Only	L-1
166	Midas Care Pharamceuticals Pvt. Ltd.	1039	Salbutamol Inhaler - Each metered dose to contain: Salbutamol 100 mcg. (Equal to or more than 120MDI)	1 Dose	Bonair Aerosol Inhalation	240 MDIs	0.36/1 MD	Paise Thirty Six Only	L-2
166	Bal Pharma Ltd	1070	Frusemide + Spironolactone Tab/Cap-Each Tab/Cap to contain: Frusemide 20 mg, Spironolactone 50 mg.	1 Tab/Cap	ALDOSTIX	10 Tab	1.81/1 Tab	Rupee One Paise Eighty One Only	L-1 (50% of Order Quantity)
166	MICRON PHARMACEUTICALS	1070	Frusemide + Spironolactone Tab/Cap - Each Tab/Cap to contain: Frusemide 20 mg, Spironolactone 50 mg.	1 Tab/Cap	M-LASITONE	10 Tab	1.81/1 Tab	Rupee One Paise Eighty One Only	L-1 (50% of Order Quantity, Class-I Local Supplier)

ESIC

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	HAB Pharmaceuticals & Research Ltd	1070	Frusemide + Spironolactone Tab/Cap - Each Tab/Cap to contain: Frusemide 20 mg, Spironolactone 50 mg.	1 Tab/Cap	URISEPT-50	10 Tab	2.64/1 Tab	Rupees Two Paise Sixty Four Only	L-3
166	MICRON PHARMACEUTICALS	1071	Acetazolamide Tab/Cap-Each Tab/Cap to contain: Acetazolamide 250 mg	1 Tab/Cap	Same as in Item	10 Tab	1.17/1 Tab	Rupee One Paise Seventeen Only	L-1
166	Wallace Pharmaceuticals Pvt. Ltd.	1072	Cinnarizine Tab/Cap - Each Tab/Cap to contain: Cinnarizine 25mg.	1 Tab/Cap	CINTIGO	10 Tab	0.27/1 Tab	Paise Twenty Seven Only	L-1
166	Morepen Laboratories Limited	1072	Cinnarizine Tab/Cap - Each Tab/Cap to contain: Cinnarizine 25mg.	1 Tab/Cap	STEDICIN 25	10 Tab	0.28/1 Tab	Paise Twenty Eight Only	L-2
166	Wings Biotech LLP	1072	Cinnarizine Tab/Cap - Each Tab/Cap to contain: Cinnarizine 25mg	1 Tab/Cap	Same as in Item	10 Tab	0.29/1 Tab	Paise Twenty Nine Only	L-3
166	Intas Pharmaceuticals Ltd.	1120	Lithium Carbonate Tab/Cap - Each Tab/Cap to contain: Lithium Carbonate 450 mg CR Tab	1 Tab/Cap	INTALITH CR 450 TAB	10 Tab	3.3/1 Tab	Rupees Three Paise Thirty Only	L-1
166	Zydus Healthcare Limited	1130	Phenytoin Inj- Each ml to contain: Phenytoin Sod. 50 mg, 2ml Amp	1 Vial/Amp	Epsolin	2ml Ampoule	4.23/1 Amp	Rupees Four Paise Twenty Three Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	HAB Pharmaceuticals & Research Ltd	1392	Oxcarbazepine Tab/Cap-Each Tab/Cap to contain: Oxcarbazepine 150mg	1 Tab/Cap	SIGEPTAL	10 Tab	2.2/1 Tab	Rupees Two Paise Twenty Only	L-1
166	LUPIN LIMITED	1392	Oxcarbazepine Tab/Cap- Each Tab/Cap to contain: Oxcarbazepine 150mg	1 Tab/Cap	LOVAX 150	15 Tab	2.29/1 Tab	Rupees Two Paise Twenty Nine Only	L-2
166	MICRON PHARMACEUTICALS	1392	Oxcarbazepine Tab/Cap-Each Tab/Cap to contain: Oxcarbazepine 150mg	1 Tab/Cap	Same as in Item	10 Tab	2.43/1 Tab	Rupees Two Paise Forty Three Only	L-3
166	Intas Pharmaceuticals Ltd.	1451	Human Coagulation Factor IX 600 IU Freeze Dried	1 Vial	Human Coagulation Factor IX I.P. 600 IU	1 Vial	5689/1 Vial	Rupees Five Thousand Six Hundred Eighty Nine Only	L-1
166	Primus Pharmaceuticals	1458	Amiodarone Tab/Cap- Each Tab/Cap to contain: Amiodarone 200mg	1 Tab/Cap	AMIVENT-200	10 Tab	3.32/1 Tab	Rupees Three Paise Thirty Two Only	L-1
166	Cipla Ltd.	1458	Amiodarone Tab/Cap- Each Tab/Cap to contain: Amiodarone 200mg	1 Tab/Cap	TACHYRA 200	10 Tab	4.15/1 Tab	Rupees Four Paise Fifteen Only	L-2
166	UNICURE INDIA LTD	1512	Ambroxol Hcl +N-Acetyl-L-Cysteine Tab/Cap - Each Tab/Cap to contain: Ambroxol Hydrochloride 30 mg, N - Acetyl - L - Cysteine 200 mg,	1 Tab/Cap	Same as in Item	10 Tab	1.99/1 Tab	Rupee One Paise Ninety Nine Only	L-1
166	Tablets (India) Limited	1512	Ambroxol Hcl +N-Acetyl-L-Cysteine Tab/Cap -Each Tab/Cap to contain: Ambroxol Hydrochloride 30mg, N - Acetyl - L - Cysteine 200 mg,	1 Tab/Cap	Ambronac Tablet	10 Tab	3.28/1 Tab	Rupees Three Paise Twenty Eight Only	L-2
166	Biodeal Pharmaceuticals Ltd.	1513	Montelukast + Levocetirizine Tab/Cap - Each Tab/Cap to contain: Montelukast 10mg, Levocetirizine Dihydrochloride 5mg,	1 Tab/Cap	Same as in Item	10 Tab	0.69/1 Tab	Paise Sixty Nine Only	L-1

ESIC

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	MICRON PHARMACEUTICALS	1513	Montelukast + Levocetirizine Tab/Cap - Each Tab/Cap to contain: Montelukast 10mg, Levocetirizine Dihydrochloride 5mg.	1 Tab/Cap	MICLUKAZET	10 Tab	0.72/1 Tab	Paise Seventy Two Only	L-2
166	UNICURE INDIA LTD	1513	Montelukast + Levocetirizine Tab/Cap - Each Tab/Cap to contain: Montelukast 10mg, Levocetirizine Dihydrochloride 5mg.	1 Tab/Cap	Same as in Item	10 Tab	0.75/1 Tab	Paise Seventy Five Only	L-3 (50% of Order Quantity)
166	Healer's Lab	1513	Montelukast + Levocetirizine Tab/Cap- Each Tab/Cap to contain: Montelukast 10mg, Levocetirizine Dihydrochloride 5mg.	1 Tab/Cap	VENTAIR-LC	10 Tab	0.75/1 Tab	Paise Seventy Five Only	L-3 (50% of Order Quantity)
166	Cipla Ltd.	1520	Inhaler -Each Inhaler to contain: Moulded Plastic Device Containing A Foil Strip With30/ 60 Regularly Placed Blisters Each Containing 50 Mcg Of Salmeterol Xinafoate And 250 Mcg Of Fluticasone Propionate	1 Dose	Seroflo Ciphaler 250	60 doses	5.33/1 Dose	Rupees Five Paise Thirty Three Only	L-1
166	Cipla Ltd.	1521	Inhaler -Each metered dose to contain: Tiotropium Bromide Monohydrate Equ. To Tiotropium 9mcg (equal to or more than 120 MDI)	1 Dose	TIOVA INHALER	200 MD	0.74/1 MD	Paise Seventy Four Only	L-1 (50% of Order Quantity)
166	Midas Care Pharamceuticals Pvt. Ltd.	1521	Inhaler - Each metered dose to contain: Tiotropium Bromide Monohydrate Equ. To Tiotropium 9mcg (equal to or more than 120 MDI)	1 dose	Bontiair A	240 MDIs	0.74/1 MD	Paise Seventy Four Only	L-1 (50% of Order Quantity, Class-I Local Supplier)
166	LUPIN LIMITED	1521	Inhaler - Each metered dose to contain: Tiotropium Bromide Monohydrate Eq. To Tiotropium 9mcg (equal to or more than 120 MDI)	1 Dose	TIATE Transhaler	180 MDI	1.34/1MD	Rupee One Paise Thirty Four Only	L-3

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Cipla Ltd.	1526	Ipratropium+ Levosalbutamol Resp - Each 2.5ml/3.0ml Respules to contain: Ipratropium I.P.500mcg, Levosalbutamol 1.25mg.	1 Respule	Duolin	3ml	2.84/1 Respule	Rupees Two Paise Eighty Four Only	L-1
166	Abbott Healthcare Pvt Ltd	1532	Isosorbide Dinitrate Tab/Cap- Each Tab/Cap to contain: Isosorbide Dinitrate 5mg	1 Tab/Cap	Sorbitrate 5	50 Tab	0.28/1 Tab	Paise Twenty Eight Only	L-1
166	Ipca Laboratories Ltd.	1532	Isosorbide Dinitrate Tab/Cap- Each Tab/Cap to contain: Isosorbide Dinitrate 5mg	1 tab/cap	Isordil-5	10 Tab	0.38/1 Tab	Paise Thirty Eight Only	L-2
166	UNICURE INDIA LTD	1532	Isosorbide Dinitrate Tab/Cap-Each Tab/Cap to contain: Isosorbide Dinitrate 5mg	1 Tab/Cap	Same as in Item	10 Tab	0.68/1 Tab	Paise Sixty Eight Only	L-3
166	MICRO LABS LTD	1573	Piracetam Tab/Cap -Each Tab/Cap to contain: Piracetam 400mg.	1 Tab/Cap	Neurocetam	10 Cap	1.48/1 Cap	Rupee One Paise Forty Eight Only	L-1
166	MICRON PHARMACEUTICALS	1573	Piracetam Tab/Cap -Each Tab/Cap to contain: Piracetam 400mg.	1 Tab/Cap	Same as in Item	10 Tab	2.25/1 Tab	Rupees Two Paise Twenty Five Only	L-2
166	Intas Pharmaceuticals Ltd.	1573	Piracetam Tab/Cap -Each Tab/Cap to contain: Piracetam 400mg.	1 Tab/Cap	CERECETAM-400	10 Tab	5.50/1 Tab	Rupees Five Paise Fifty Only	L-3
166	Signature Phytochemical Industries	1575	Pregabalin + Methylcobalamin Tab/Cap, Each Tab/Cap. to contain: Pregabalin 75 mg, Methylcobalamin 750mcg.	1 Tab/Cap	NERVIGESIC-M 75	10 Cap	0.98/1 Cap	Paise Ninety Eight Only	L-1

ESIC

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	RIVPRA FORMULATION PVT. LTD.	1575	Pregabalin + Methylcobalamin Tab/Cap, Each Tab/Cap. to contain: Pregabalin 75 mg, Methylcobalamin 750mcg	1 Tab/Cap	PREGAMEN-M	10 Cap	1.11/1 Cap	Rupee One Paise Eleven Only	L-2
166	MASCOT HEALTH SERIES PVT LTD	1575	Pregabalin + Methylcobalamin Tab/Cap, Each Tab/Cap. to contain: Pregabalin 75 mg, Methylcobalamin 750mcg	1 Tab/Cap	PREGABON-M	10 Cap	1.12/1 Cap	Rupee One Paise Twelve Only	L-3
166	HAB Pharmaceuticals & Research Ltd	1576	Gabapentine +Mehylcobalamin Tab/Cap-Each Tab/cap. to contain: Gabapentine 300mg, Mehylcobalamin 500mcg.	1 Tab/Cap	GABASIGN-ME	10 Tab	1.38/1 Tab	Rupee One Paise Thirty Eight Only	L-1
166	Healer's Lab	1576	Gabapentine + Mehylcobalamin Tab/Cap -Each Tab/cap. to contain: Gabapentine 300 mg, Mehylcobalamin 500mcg.	1 Tab/Cap	GABANERVE	10 Tab	1.43/1 Tab	Rupee One Paise Forty Three Only	L-2
166	MESMER PHARMACEUTICALS	1576	Gabapentine +Mehylcobalamin Tab/Cap - EachTab/cap.to contain: Gabapentine300mg, Mehylcobalamin 500mcg.	1 Tab/Cap	Progaba-AM	10 Tab	1.44/1 Tab	Rupee One Paise Forty Four Only	L-3
166	USV Private Limited	1664	Cough Syrup : Each100ml solution to contain: Dried Ivy leaf extract 0.7gm, 100ml Bottle	1ml	Prospan	100ml bottle	0.75/1ml	Paise Seventy Five Only	L-1
166	Midas Care Pharamceuticals Pvt. Ltd.	1665	Inhaler-Each metered dose to contain : Tiotropium 9mcg, Formoterol 6 mcg, Ciclesonide 200mcg (CFC Free)(equal to or more than 120 MDI)	1 dose	Fortropium-C	240 MDIs	1.05/1MD	Rupee One Paise Five Only	L-1
166	LUPIN LIMITED	1665	Inhaler - Each metered dose to contain:Tiotropium 9mcg,Formoterol 6 mcg, Ciclesonide 200mcg (CFC Free)(equal to or more than 120 MDI)	1 Dose	TRIMIUM Transhaler	180 MDIs	1.84/1MD	Rupee One Paise Eighty Four Only	L-2
166	Abbott Healthcare Pvt Ltd	1671	Acenocoumarol Tab/Cap - Each Tab/Cap to contain: Acenocoumarol 4mg	1 Tab/Cap	Acitrom 4	30 Tab	1.5/1 Tab	Rupee One Paise Fifty Only	L-1


DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Macleods Pharmaceuticals Limited	1671	Acenocoumarol Tab/Cap -Each Tab/Cap to contain: Acenocoumarol 4mg	1 Tab/Cap	ACENOMAC 4	10 Tab	4.30/1 Tab	Rupees Four Paise Thirty Only	L-2
166	Healer's Lab	1745	Doxofylline Tab/Cap -Each Tab/Cap to contain: Doxofylline 400mg	1 Tab/Cap	P-DOX	10 Tab	1.24/1 Tab	Rupee One Paise Twenty Four Only	L-1
166	Wings Biotech LLP	1745	Doxofylline Tab/Cap - Each Tab/Cap to contain: Doxofylline 400mg	1 Tab/Cap	Same as in Item	10 Tab	1.25/1 Tab	Rupee One Paise Twenty Five Only	L-2
166	HAB Pharmaceuticals & Research Ltd	1745	Doxofylline Tab/Cap -Each Tab/Cap to contain: Doxofylline 400mg	1 Tab/Cap	DOXOSIGN	10 Tab	1.38/1 Tab	Rupee One Paise Thirty Eight Only	L-3
166	Reliance Life Sciences Pvt. Ltd.	1746	Omaliizumab Inj -Each vial to contain: Omaliizumab 150mg	1 Vial	OmaliRel	1 Vial	8800/1 Vial	Rupees Eight Thousand Eight Hundred Only	L-1
166	Signature Phytochemical Industries	1753	Telmisartan, Amlodipine Tab/Cap - Each Tab/Cap to contain: Telmisartan 40 mg, Amlodipine Besylate equivalent to Amlodipine 5mg	1 Tab/Cap	TELMISIGN AM	15 Tab	0.68/1 Tab	Paise Sixty Eight Only	L-1
166	ULTRA DRUGS PVT. LTD.	1753	Telmisartan, Amlodipine Tab/Cap - Each Tab/Cap to contain: Telmisartan 40mg, Amlodipine Besylate equivalent to Amlodipine 5mg	1 Tab/Cap	Same as in Item	10 Tab	0.69/1 Tab	Paise Sixty Nine Only	L-2
166	Healer's Lab	1753	Telmisartan, Amlodipine Tab/Cap - Each Tab/Cap to contain: Telmisartan 40mg, Amlodipine Besylate equivalent to Amlodipine 5mg	1 Tab/Cap	T-SARTAN-AM	10 Tab	0.74/1 Tab	Paise Seventy Four Only	L-3
166	Cipla Ltd.	1839	Autohaler-Each Deliver Dose Of Autohaler/Syncobreath to contain: Formoterol Fumarate Dihydrate IP 6 mcg, Budesonide IP 200 mcg Equal to or more than 120 MDI	1 Dose	FORACORT 200 Synchronbreath	120 MD	3.21/1 MD	Rupees Three Paise Twenty One Only	L-1
166	Cipla Ltd.	1846	Propranolol Tab/Cap-Each Tab/Cap to contain: Propranolol 10mg	1 Tab/Cap	CIPLAR-10	15 Tab	0.27/1 Tab	Paise Twenty Seven Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Abbott Healthcare Pvt Ltd	1846	Propranolol Tab/Cap- Each Tab/Cap to contain: Propranolol 10mg	1 Tab/Cap	Inderal 10	15 Tab	0.32/1 Tab	Paise Thirty Two Only	L-2
166	Intas Pharmaceuticals Ltd.	1846	Propranolol Tab/Cap- Each Tab/Cap to contain: Propranolol 10mg	1 tab/cap	PROVANOL 10	10 Tab	0.80/1 Tab	Paise Eighty Only	L-3
166	Macleods Pharmaceuticals Limited	1850	Labetalol Tab/Cap -Each Tab/Cap to contain: Labetalol 100mg	1 Tab/Cap	LABETAMAC	10 Tab	2.43/1 Tab	Rupees Two Paise Forty Three Only	L-1
166	Macleods Pharmaceuticals Limited	1851	Moxonidine Tab/Cap-Each Tab/Cap to contain: Moxonidine 0.2mg	1 Tab/Cap	MOXOVAS 0.2	10 Tab	4.30/1 Tab	Rupees Four Paise Thirty Only	L-1
166	Morepen Laboratories Limited	1852	Cilnidipine Tab/Cap - Each Tab/Cap to contain: Cilnidipine 10 mg	1 Tab/Cap	CILINIMORE-10	10 Tab	0.49/1 Tab	Paise Forty Nine Only	L-1
166	MANKIND PHARMA LIMITED	1852	Cilnidipine Tab/Cap -Each Tab/Cap to contain: Cilnidipine 10 mg	1 Tab/Cap	Same as in Item	15 Tab	0.64/1 Tab	Paise Sixty Four Only	L-2
166	RIVPRA FORMULATION PVT. LTD.	1852	Cilnidipine Tab/Cap - Each Tab/Cap to contain: Cilnidipine 10 mg	1 Tab/Cap	Same as in Item	10 Tab	0.65/1 Tab	Paise Sixty Five Only	L-3
166	MESMER PHARMACEUTICALS	1854	Cilostazol Tab/Cap- Each Tab/Cap to contain: Cilostazol 100mg	1 Tab/Cap	Cilotab-100	10 Tab	1.98/1 Tab	Rupee One Paise Ninety Eight Only	L-1
166	Cipla Ltd.	1882	Lamotrigine Dispersible Tab/Cap-Each Disp Tab/Cap to contain: Lamotrigine 25mg	1 Tab/Cap	LAMETEC-25 DT	10 Tab	0.64/1 Tab	Paise Sixty Four Only	L-1
166	Torrent Pharmaceuticals Ltd.	1882	Lamotrigine Dispersible Tab/Cap-Each Disp Tab/Cap to contain: Lamotrigine 25mg	1 Tab/Cap	LAMITOR DT-25	15 Tab	0.75/1 Tab	Paise Seventy Five Only	L-2
166	BDR Pharmaceuticals International Private Limited	1885	Levetiracetam Inj-Each ml to contain: Levetiracetam 100 mg, 5ml Vial/Amp	1 Vial/Amp	BDTERA 100mg/ml	5 ml Vial	16.12/1 Vial	Rupees Sixteen Paise Twelve Only	L-1

कृषि नीति
ESIC


36 | Page

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	LUPIN LIMITED	1885	Levetiracetam Inj- Each ml to contain: Levetiracetam100 mg,5ml Vial/Amp	1 Vial/Amp	EPILIVE IV	5 ml Vial	18.90/1 Vial	Rupees Eighteen Paise Ninety Only	L-2
166	Intas Pharmaceuticals Ltd.	1885	Levetiracetam Inj- Each ml to contain: Levetiracetam100 mg,5ml Vial/Amp	1 Vial/Amp	LEVERA INJECTION	5 ml Vial	45.00/1 Vial	Rupees Forty Five Only	L-3
166	Cipla Ltd.	2016	Budesonide 200mcg + Formoterol Fumarate 6mcg Rotocap-Each Rotacap to contain: Budesonide 200mcg+Formoterol Fumarate 6mcg	1 Cap	FORACORT 200 ROTACAPS	30 Rotacap	0.62/1 Rotacap	Paise Sixty Two Only	L-1
166	Biodeal Pharmaceuticals Ltd.	2016	Budesonide 200mcg + Formoterol Fumarate 6mcg Rotocap-Each Rotacap to contain: Budesonide 200mcg + Formoterol Fumarate 6mcg	1 Cap	Same as in Item	30 Rotacap	0.63/1 Rotacap	Paise Sixty Three Only	L-2
166	LUPIN LIMITED	2016	Budesonide 200mcg + Formoterol Fumarate 6mcg Rotocap-Each Rotacap to contain: Budesonide 200mcg + Formoterol Fumarate 6mcg	1 Cap	Same as in Item	30 Rotacap	0.67/1 Rotacap	Paise Sixty Seven Only	L-3
166	RIVPRA FORMULATION PVT. LTD.	2026	N-Acetyl Cysteine Tab/Cap-Each Tab/Cap to contain: N-Acetylcysteine 600mg	1 Tab/Cap	MUCIMEN-600	10 Tab	2.90/1 Tab	Rupees Two Paise Ninety Only	L-1
166	Med Manor Organics Pvt. Ltd.	2026	N-Acetyl Cysteine Tab/Cap-Each Tab/Cap to contain: N-Acetylcysteine 600mg	1 Tab/Cap	NAC 600	10 Tab	3.33/1 Tab	Rupees Three Paise Thirty Three Only	L-2
166	Cipla Ltd.	2026	N-Acetyl Cysteine Tab/Cap-Each Tab/Cap to contain: N-Acetylcysteine 600mg	1 Tab/Cap	MUCINAC 600	10 Tab	3.65/1 Tab	Rupees Three Paise Sixty Five Only	L-3
166	LUPIN LIMITED	2062	Indacaterol + Glycopyrronium Tab/Cap Each Tab/Cap to contain: 143mcg Indacaterol Maleate Eqv. to 110mcg Indacaterol & 63mcg Glycopyrronium Bromide Eqv. to 50 mcg Glycopyrronium.	1 Tab/Cap	LOFTAIR	30 Cap	10.97/1 Cap	Rupees Ten Paise Ninety Seven Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Cipla Ltd.	2062	Indacaterol + Glycopyrronium Tab/Cap- Each Tab/Cap to contain: 143 mcg Indacaterol Maleate Eqv. to 110 mcg Indacaterol & 63 mcg Glycopyrronium Bromide Eqv to 50 mcg Glycopyrronium.	1 Tab/Cap	Nistami	30 Cap	12.30/1 Cap	Rupees Twelve Paise Thirty Only	L-2
166	RPG Life Sciences Ltd	2212	Epleronone Tab/Cap-Each Film Coated Tab/Cap to contain: Epleronone 25mg	1 Tab/Cap	Exinia 25	7 Tab	6.67/1 Tab	Rupees Six Paise Sixty Seven Only	L-1
166	RIVPRA FORMULATION PVT. LTD.	2213	Clonidine Tab/Cap-Each Tab/Cap to contain: Clonidine 0.1 mg	1 Tab/Cap	Same as in Item	10 Tabs	1.11/1 Tab	Rupee One Paise Eleven Only	L-1
166	Intas Pharmaceuticals Ltd.	2214	Memantine Tab/Cap-Each Tab/Cap to contain: Memantine Hcl 10mg Tab	1 Tab/Cap	NEMDAA 10	10 Tab	10.76/1 Tab	Rupees Ten Paise Seventy Six Only	L-1
166	Intas Pharmaceuticals Ltd.	2301	Carvedilol Phosphate Tab/Cap-Each Tab/Cap to contain: Carvedilol Phosphatel 10mg Tab	1 Tab/Cap	CARCA CR 10	15 Tab	7.61/1 Tab	Rupees Seven Paise Sixty One Only	L-1
166	Torrent Pharmaceuticals Ltd.	2304	Acetyl Salicylic Acid + Clopidigrel Tab/Cap-Each Tab/Cap to contain: Acetyl Salicylic Acid 75mg, Clopidigrel 75mg	1 Tab/Cap	DEPLATT A 75	15 Tab	2.02/1 Tab	Rupees Two Paise Two Only	L-1
166	LUPIN LIMITED	2304	Acetyl Salicylic Acid + Clopidigrel Tab/Cap-Each Tab/Cap to contain: Acetyl Salicylic Acid 75mg, Clopidigrel 75mg	1 Tab/Cap	CLOPITAB-A 75	15 Cap	2.49/1 Cap	Rupees Two Paise Forty Nine Only	L-2
166	MICRO LABS LTD	2305	Trimetazidine Tab/Cap-Each PLAIN/SR/CR/DR/ER/MR Tab/Cap to contain: Trimetazidine 60mg	1 Tab/Cap	Carvidon-OD	15 Tab	1.94/1 Tab	Rupee One Paise Ninety Four Only	L-1
166	Ipca Laboratories Ltd.	2305	Trimetazidine Tab/Cap-Each PLAIN/SR/CR/DR/ER/MR Tab/Cap to contain: Trimetazidine 60mg	1 Tab/Cap	Metagard CR-60	10 Tab	1.99/1 Tab	Rupee One Paise Ninety Nine Only	L-2

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	MODI MUNDIPHARMA PVT LTD	2305	Trimetazidine Tab/Cap-Each PLAIN/SR/CR/DR/ER/MR Tab/Cap to contain: Trimetazidine 60mg	1 Tab/Cap	TRIMACONTIN 60	100 Tab	2.07/1 Tab	Rupees Two Paise Seven Only	L-3
166	Ipca Laboratories Ltd.	2308	Chlorthalidone Tab/Cap-Each Tab/Cap to contain: Chlorthalidone 6.25mg	1 Tab/Cap	CTD-6.25	15 Tab	0.61/1 Tab	Paise Sixty One Only	L-1
166	LUPIN LIMITED	2308	Chlorthalidone Tab/Cap-Each Tab/Cap to contain: Chlorthalidone 6.25mg	1 Tab/Cap	LUPICLOR 6.25	15 Tab	0.64/1 Tab	Paise Sixty Four Only	L-2
166	T. Walker's Pharmaceuticals Pvt Ltd	2310	AMINOPHYLLINE INJECTION IP 10 ML AMPOULE: AMINOPHYLLINE IP (25 mg) Water for Injection IP (Q. S. TO 1.0 ml)	1 Vial/AMP	Same as in Item	10ml Amp	9.15/1 Amp	Rupees Nine Paise Fifteen Only	L-1
166	Torrent Pharmaceuticals Ltd.	2313	Venlafaxine CR/ SR/ DR/ MR Tab/Cap-Each CR/ SR/ DR/ MR Tab/Cap to contain: Venlafaxine 37.5mg	1 Tab/Cap	VENLIFT OD-37.5	10 Cap	3.02/1 Cap	Rupees Three Paise Two Only	L-1
166	Intas Pharmaceuticals Ltd.	2313	Venlafaxine Tab/Cap-Each Tab/Cap to contain: Venlafaxine 37.5 mg ER Tab	1 Tab/Cap	VENTAB XL 37.5	10 Tab	3.74/1 Tab	Rupees Three Paise Seventy Four Only	L-2
166	Intas Pharmaceuticals Ltd.	2428	Donepezil Tab/Cap-Each Tab/Cap to contain: Donepezil Hcl 10 mg Tab	1 Tab/Cap	ALZIL 10	10 Tab	9.31/1 Tab	Rupees Nine Paise Thirty One Only	L-1
166	Morepen Laboratories Limited	2430	Levetiracetam Syp- Each ml to contain: Levetiracetam 100mg, 100ml Bottle	1ml	LEVETAFINE	100ml Bottle	0.60/1ml	Paise Sixty Only	L-1
166	UNICURE INDIA LTD	2430	Levetiracetam Syp-Each ml to contain: Levetiracetam 100mg, 100ml Bottle	1ml	Same as in Item	100ml Bottle	0.76/1ml	Paise Seventy Six Only	L-2
166	MANKIND PHARMA LIMITED	2431	Etizolam Tab/Cap-Each Tab/Cap contain: Etizolam 0.5mg	1 Tab/Cap	SOLOPOSE-0.5 MD	10 Tab	0.90/1 Tab	Paise Ninety Only	L-1
166	Macleods Pharmaceuticals Limited	2431	Etizolam Tab/Cap-Each Tab/Cap contain: Etizolam 0.5mg	1 Tab/Cap	ETIZOLA 0.5	15 Tab	3.10/1 Tab	Rupees Three Paise Ten Only	L-2
166	Intas Pharmaceuticals Ltd.	2431	Etizolam Tab/Cap-Each Tab/Cap contain: Etizolam 0.5mg	1 Tab/Cap	ETILAAM-0.5	15 Tab	4.02/1 Tab	Rupees Four Paise Two Only	L-3

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Intas Pharmaceuticals Ltd.	2432	Sodium Valproate Injection, 100 mg/ml	1 Vial/Amp	VALPROL	5ml Amp	32.00/1 Amp	Rupees Thirty Two Only	L-1
166	Cipla Ltd.	2435	Warfarin Sodium Tab/Cap-Each Tab/Cap contain: Warfarin Sodium 3mg	1 Tab/Cap	WARF-3	30 Tab	0.32/1 Tab	Paise Thirty Two Only	L-1
166	Cipla Ltd.	2436	Warfarin Sodium Tab/Cap-Each Tab/Cap contain: Warfarin Sodium 2mg	1 Tab/Cap	WARF-2	30 Tab	0.32/1 Tab	Paise Thirty Two Only	L-1
166	ULTRA DRUGS PVT. LTD.	2439	Telmisartan+Hydrochlorthiazide Tab/Cap-Each Tab/Cap contain: Telmisartan 40mg + Hydrochlorthiazide 12.5mg	1 Tab/Cap	Same as in Item	10 Tab	0.70/1 Tab	Paise Seventy Only	L-1
166	Signature Phytochemical Industries	2439	Telmisartan+Hydrochlorthiazide Tab/Cap- Each Tab/Cap contain: Telmisartan 40mg + Hydrochlorthiazide 12.5mg	1 Tab/Cap	TELMISIGN H	15 Tab	0.72/1 Tab	Paise Seventy Two Only	L-2
166	Healer's Lab	2439	Telmisartan+ Hydrochlorthiazide Tab/Cap-Each Tab/Cap contain: Telmisartan 40mg + Hydrochlorthiazide 12.5mg	1 Tab/Cap	T-SARTAN-H	10 Tab	0.73/1 Tab	Paise Seventy Three Only	L-3
166	Primus Pharmaceuticals	2440	Prasugrel Tab/Cap-Each Tab/Cap contain: Prasugel 5mg	1 Tab/Cap	PRASURUS-5	10 Tab	2.90/1 Tab	Rupees Two Paise Ninety Only	L-1
166	Signature Phytochemical Industries	2440	Prasugrel Tab/Cap-Each Tab/Cap contain: Prasugel 5mg	1 Tab/Cap	PROFFIENT-5	10 Tab	4.08/1 Tab	Rupees Four Paise Eight Only	L-2
166	Primus Pharmaceuticals	2441	Rivaroxaban Tab/Cap-Each Tab/Cap contain: Rivaroxaban 10mg	1 Tab/Cap	RIVAPRIME-10	10 Tab	1.09/1 Tab	Rupee One Paise Nine Only	L-1
166	Morepen Laboratories Limited	2441	Rivaroxaban Tab/Cap- Each Tab/Cap contain: Rivaroxaban 10mg	1 Tab/Cap	Rivaright 10	30 Tab	1.34/1 Tab	Rupee One Paise Thirty Four Only	L-2

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	BDR Pharmaceuticals International Private Limited	2441	Rivaroxaban Tab/Cap-Each Tab/Cap contain: Rivaroxaban 10mg	1 Tab/Cap	BDRIVO 10	10 Tab	1.39/1 Tab	Rupee One Paise Thirty Nine Only	L-3
166	MESMER PHARMACEUTICALS	2442	Topiramate Tab/Cap-Each Tab/Cap contain: Topiramate 50mg	1 Tab/Cap	Topamed-50	10 Tab	0.70/1 Tab	Paise Seventy Only	L-1
166	Signature Phytochemical Industries	2442	Topiramate Tab/Cap-Each Tab/Cap contain: Topiramate 50mg	1 Tab/Cap	TOPRASIGN	10 Tab	4.50/1 Tab	Rupees Four Paise Fifty Only	L-2
166	MESMER PHARMACEUTICALS	2444	Pramipexole Dihydrochloride Tab/Cap-Each Tab/Cap contain: Pramipexole Dihydrochloride 1mg	1 Tab/Cap	Pramiset-1	10 Tab	6.89/1 Tab	Rupees Six Paise Eighty Nine Only	L-1
166	Cipla Ltd.	2450	Budesonide Respule-Each Respule to contain: Budesonide 0.5mg	1 Respule	BUDECORT RESPULES	2ml	4.05/1 Respule	Rupees Four Paise Five Only	L-1
166	Primus Pharmaceuticals	2451	Diltiazem Hydrochloride Gel-Each Tube to contain: Diltiazem Hydrochloride 2%	30gm Tube	CARDIRUS GEL	30gm Tube	77/1 Tube	Rupees Seventy Seven Only	L-1
166	Troikaa Pharmaceuticals Limited	2451	Diltiazem Hydrochloride Gel-Each Tube to contain: Diltiazem Hydrochloride 2%	30gm Tube	Diltigesic Gel	30gm Tube	120/1 Tube	Rupees One Hundred Twenty Only	L-2
166	Theon Pharmaceuticals Limited	2569	Acebrophylline Tab/Cap: Each tab/cap to contain Acebrophylline 200mg	1 Tab/Cap	Acebrophylline Sustained Release Tablets 200 mg	10 Tab	1.46/1 Tab	Rupee One Paise Forty Six Only	L-1
166	Zuventus Healthcare Limited	2569	Acebrophylline Tab/Cap: Each tab/cap to contain Acebrophylline 200mg	1 Tab/Cap	Brophyle SR	10 Tab	2.30/1 Tab	Rupees Two Paise Thirty Only	L-2

ESIC

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Intas Pharmaceuticals Ltd.	2569	Acebrophylline Tab/Cap: Each tab/cap to contain Acebrophylline 200mg	1 Tab/Cap	BIGBRO OD	10 Tab	5.20/1 Tab	Rupees Five Paise Twenty Only	L-3
166	Theon Pharmaceuticals Limited	2570	Acebrophylline+Acetylcysteine Tab/Cap: Each tab/cap to contain Acebrophylline 100mg+Acetylcysteine 600mg	1 Tab/Cap	Acebrophylline & Acetylcysteine Tablets	10 Tab	5.72/1 Tab	Rupees Five Paise Seventy Two Only	L-1
166	Cipla Ltd.	2573	Ambroxol Hydrochloride Respules: Each 2 ml Respule contain: Ambroxol Hydrochloride 15mg.	1 Respule	INHALEX RESPULES	2ml	3.80/ 1 Respule	Rupees Three Paise Eighty Only	L-1
166	Biodeal Pharmaceuticals Ltd.	2575	Amisulpride Tab/Cap :Each Tab/cap to contain Amisulpride 100 mg.	1 Tab/Cap	Amisulpride Tablets IP	10 Tab	1.11/1 Tab	Rupee One Paise Eleven Only	L-1
166	MESMER PHARMACEUTICALS	2575	Amisulpride Tab/Cap :Each Tab/cap to contain Amisulpride 100 mg.	1 Tab/Cap	Amide-100	10 Tab	2.08/1 Tab	Rupees Two Paise Eight Only	L-2
166	LOGOS PHARMA	2575	Amisulpride Tab/Cap :Each Tab/cap to contain Amisulpride 100 mg.	1 Tab/Cap	Amisulpride Tablets IP	10 Tab	3.00/1 Tab	Rupees Three Only	L-3
166	Intas Pharmaceuticals Ltd.	2577	Aripiprazole 10mg Tab/Cap: Each Tab/cap to contain Aripiprazole 10mg	1 Tab/Cap	ASPRITO-10	15 Tab	8.06/1 Tab	Rupees Eight Paise Six Only	L-1
166	Intas Pharmaceuticals Ltd.	2578	Atomoxetine 10mg Tab/Cap: Each Tab/cap to contain Atomoxetine Hcl 10mg	1 Tab/Cap	AXEPTA-10	10 Tab	7.10/1 Tab	Rupees Seven Paise Ten Only	L-1
166	Morepen Laboratories Limited	2579	Atorvastatin + Fenofibrate -Each Tab/Cap to contain:Atorvastatin 10mg+ Fenofibrate 160mg	1 Tab/Cap	TOR HDL TG	10 Tab	1.20/1 Tab	Rupee One Paise Twenty Only	L-1
166	MANKIND PHARMA LIMITED	2579	Atorvastatin + Fenofibrate -Each Tab/Cap to contain:Atorvastatin 10mg+ Fenofibrate 160mg	1 Tab/Cap	LIPIKIND-F	10 Tab	1.29/1 Tab	Rupee One Paise Twenty Nine Only	L-2
166	Theon Pharmaceuticals Limited	2579	Atorvastatin + Fenofibrate -Each Tab/Cap to contain:Atorvastatin 10mg+ Fenofibrate 160mg	1 Tab/Cap	Same as in Item	10 Tab	1.43/1 Tab	Rupee One Paise Forty Three Only	L-3
166	MANKIND PHARMA LIMITED	2582	Bisoprolol Tab/Cap: Each Tab/cap to contain Bisoprolol 2.5 mg	1 Tab/Cap	BISOHEART 2.5	10 Tab	0.84/1 Tab	Paise Eighty Four Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Torrent Pharmaceuticals Ltd.	2582	Bisoprolol Tab/Cap: Each Tab/cap to contain Bisoprolol 2.5 mg	1 Tab/Cap	CORBIS-2.5	15 Tab	1.08/1 Tab	Rupee One Paise Eight Only	L-2
166	Intas Pharmaceuticals Ltd.	2582	Bisoprolol Tab/Cap: Each Tab/cap to contain Bisoprolol 2.5 mg	1 Tab/Cap	BISELECT 2.5	10 Tab	2.23/1 Tab	Rupees Two Paise Twenty Three Only	L-3
166	Abbott Healthcare Pvt Ltd	2585	Chlordiazepoxide Tab/Cap: Each Tab/cap to contain Chlordiazepoxide 10mg	1 Tab/Cap	Librium 10	15 Tab	0.43/1 Tab	Paise Forty Three Only	L-1
166	Abbott Healthcare Pvt Ltd	2586	Chlordiazepoxide Tab/Cap: Each Tab/cap to contain Chlordiazepoxide 25mg	1 Tab/Cap	Librium 25	15 Tab	0.86/1 Tab	Paise Eighty Six Only	L-1
166	MICRO LABS LTD	2587	Clonazepam+Escitalopram Tab/Cap: Each Tab/cap to contain Clonazepam (0.5mg) + Escitalopram(10mg).	1 Tab/Cap	PETRIL PLUS	15 Tab	1.34/1 Tab	Rupee One Paise Thirty Four Only	L-1
166	MDC PHARMACEUTICALS LIMITED	2587	Clonazepam+Escitalopram Tab/Cap: Each Tab/cap to contain Clonazepam (0.5mg) + Escitalopram(10mg).	1 Tab/Cap	Same as in Item	10 Tab	1.35/1 Tab	Rupee One Paise Thirty Five Only	L-2
166	MANKIND PHARMA LIMITED	2587	Clonazepam+Escitalopram Tab/Cap: Each Tab/cap to contain Clonazepam (0.5mg) + Escitalopram(10mg).	1 Tab/Cap	CLONAFIT-PLUS	10 Tab	1.85/1 Tab	Rupee One Paise Eighty Five Only	L-3
166	Intas Pharmaceuticals Ltd.	2590	Donepezil Hcl 5 mg + Memantine Hcl 5 mg Tab	1 Tab/Cap	ALZIL-M 5 TAB	10 Tab	13.30/1 Tab	Rupees Thirteen Paise Thirty Only	L-1
166	Pulse Pharmaceuticals Pvt Ltd	2591	Melatonin Spray: Each 0.2 ml liquid contains Melatonin 0.3 MG ,12ml Bottle	1ml	Melsoma Oral Nano Spray	12ml bottle	23.51/1ml	Rupees Twenty Three Paise Fifty One Only	L-1
166	Zydus Healthcare Limited	2592	Glycopyrrolate + Formoterol Multidose Inhaler: Glycopyrrolate I.P. 9.0 mcg, Formoterol Fumarate Dihydrate I.P. eq. to Formoterol Fumarate 4.8 mcg, 120 MDI	1 Metered Dose	Forglyn Inhaler	120 MDI	2.09/1 MD	Rupees Two Paise Nine Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	LUPIN LIMITED	2593	Mometasone+ Glycopyrronium+ Indacaterol capsule: Each capsule contains: Mometasone Furoate eq. to 136 mcg of Mometasone Furoate IP 160 mcg, Glycopyrronium Bromide eq. to 46 mcg of Glycopyrronium Ph. Eur 63 mcg, Indacaterol Acetate eq. to 114 mcg of Indacaterol IH 173 mcg inhalation powder	1 Cap	DIFIZMA	10 Cap	22.90/1 Cap	Rupees Twenty Two Paise Ninety Only	L-1
166	LUPIN LIMITED	2594	Vilanterol+Fluticasone+Glycopyrronium capsules: Each capsule contains: Vilanterol Trifenatate eq. to Vilanterol 25 mcg, Fluticasone Furoate 100 mcg, Glycopyrronium Bromide Ph. Eur eq. to Glycopyrronium 50 mcg, excipients q.s.	1 Cap	LUPIN VILFURO-G	10 Cap	9.90/1 Cap	Rupees Nine Paise Ninety Only	L-1
166	Zydus Healthcare Limited	2594	Vilanterol + Fluticasone + Glycopyrronium capsules: Each capsule contains: Vilanterol Trifenatate eq. to Vilanterol 25 mcg, Fluticasone Furoate 100 mcg, Glycopyrronium Bromide Ph. Eur eq. to Glycopyrronium 50 mcg, excipients-q.s.	1 Cap	ODihale G 100 RESPICAPS	30 Cap	13.73/1 Cap	Rupees Thirteen Paise Seventy Three Only	L-2
166	Ajanta Pharma Ltd.	2595	Metoprolol+ Amlodipine+Telmisartan: Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50 mg equivalent to Metoprolol Tartrate 50 mg (As extended release) Amlodipine Besilate IP equivalent to Amlodipine 5 mg, Telmisartan IP 40mg	1 tab/cap	MET XL AMT 50/5/40	10 Tab	8.10/1 Tab	Rupees Eight Paise Ten Only	L-1

ESIC

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Servier India Private Limited	2596	Perindopril+Indapamide+Amlodipine Tab/Cap: Each Uncoated tablet contains Perindopril Erbumine IP 4MG Indapamide IP 1.25MG Amlodipine Besylate I.P. equivalent to Amlodipine 5mg	1 Tab/Cap	TRIPLIXAM 4mg/1.25mg/5 mg	10 Tab	18.30/1 Tab	Rupees Eighteen Paise Thirty Only	L-1
166	Servier India Private Limited	2597	Perindopril+Amlodipine Tab/Cap: Each uncoated tablet contains perindopril Erbumine I.P. 4mg+Amlodipine Besylate IP equivalent to Amlodipine 10mg	1 Tab/Cap	COVERSYL AM 4mg/10mg	10 Tab	18.30/1 Tab	Rupees Eighteen Paise Thirty Only	L-1
166	Ajanta Pharma Ltd.	2598	Efonidipine Hydrochloride Ethanolate tab/cap: Each Tab/cap to contain Efonidipine Hydrochloride Ethanolate 20mg	1 Tab/Cap	EFONTA 20	15 Tab	5.40/1 Tab	Rupees Five Paise Forty Only	L-1
166	Zuventus Healthcare Limited	2598	Efonidipine Hydrochloride Ethanolate tab/cap: Each Tab/cap to contain Efonidipine Hydrochloride Ethanolate 20mg	1 Tab/Cap	EFNOCAR-20	10 Tab	7.30/1 Tab	Rupees Seven Paise Thirty Only	L-2
166	MICRO LABS LTD	2602	Fluvoxamine tab/cap: Each Tab/cap to contain Fluvoxamine 100 mg	1 Tab/Cap	VOXAMIN-100	10 Tab	5.4/1 Tab	Rupees Five Paise Forty Only	L-1
166	MESMER PHARMACEUTICALS	2602	Fluvoxamine tab/cap: Each Tab/cap to contain Fluvoxamine 100 mg	1 Tab/Cap	Voxidep-100	10 Tab	7.55/1 Tab	Rupees Seven Paise Fifty Five Only	L-2
166	Intas Pharmaceuticals Ltd.	2602	Fluvoxamine tab/cap: Each Tab/cap to contain Fluvoxamine 100 mg	1 Tab/Cap	FREXT 100	10 Tab	20.85/1 Tab	Rupees Twenty Paise Eighty Five Only	L-3
166	Intas Pharmaceuticals Ltd.	2603	Flupentixol tab/cap: Each Tab/cap to contain Flupentixol 1mg	1 Tab/Cap	SPENZO-1	10 Tab	4.40/1 Tab	Rupees Four Paise Forty Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Intas Pharmaceuticals Ltd.	2604	Flupentixol tab/cap: Each Tab/cap to contain Flupentixol 3mg	1 Tab/Cap	SPENZO-3	10 Tab	7.96/1 Tab	Rupees Seven Paise Ninety Six Only	L-1
166	MESMER PHARMACEUTICALS	2606	Fluvoxamine tab/cap: Each Tab/cap to contain Fluvoxamine 50mg	1 Tab/Cap	Voxidep-50	10 Tab	3.75/1 Tab	Rupees Three Paise Seventy Five Only	L-1
166	Intas Pharmaceuticals Ltd.	2606	Fluvoxamine tab/cap: Each Tab/cap to contain Fluvoxamine 50mg	1 Tab/Cap	FREXT 50	10 Tab	12.14/1 Tab	Rupees Twelve Paise Fourteen Only	L-2
166	LUPIN LIMITED	2610	Isosorbide Di Nitrate+Hydralazine tab/cap:Each Tab/cap to contain Iso sorbide Di nitrate 20mg + Hydralazine 37.5mg	1 Tab/Cap	ISOLAZINE	15 Tab	5.49/1 Tab	Rupees Five Paise Forty Nine Only	L-1
166	MESMER PHARMACEUTICALS	2612	Lacosamide Tab/Cap: Each Tab/Cap to contain Lacosamide 50mg	1 Tab/Cap	Lacoptal-50	10 Tab	0.99/1 Tab	Paise Ninety Nine Only	L-1
166	LUPIN LIMITED	2612	Lacosamide Tab/Cap: Each Tab/Cap to contain Lacosamide 50mg	1 Tab/Cap	LACONEXT 50	15 Tab	1.89/1 Tab	Rupee One Paise Eighty Nine Only	L-2
166	Torrent Pharmaceuticals Ltd.	2612	Lacosamide Tab/Cap: Each Tab/Cap to contain Lacosamide 50mg	1 Tab/Cap	LACOSAM 50	15 Tab	2.45/1 Tab	Rupees Two Paise Forty Five Only	L-3
166	Torrent Pharmaceuticals Ltd.	2614	Levosulpiride Tab/Cap: Each Tab/cap contains Levosulpiride 25mg	1 Tab/Cap	LEVAZEO 25	10 Tab	1.40/1 Tab	Rupee One Paise Forty Only	L-1
166	LOGOS PHARMA	2614	Levosulpiride Tab/Cap: Each Tab/cap contains Levosulpiride 25mg	1 Tab/Cap	Same as in Item	10 Tab	1.50/1 Tab	Rupee One Paise Fifty Only	L-2

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Healer's Lab	2614	Levosulpiride Tab/Cap: Each Tab/cap contains Levosulpiride 25mg	1 Tab/Cap	L-PRIDE	10 Tab	3.50/1 Tab	Rupees Three Paise Fifty Only	L-3
166	Centaur Pharmaceuticals Pvt. Ltd.	2623	METOLAZONE Tab/Cap: Each Tab/cap to contain METALAZONE 2.5mg	1 Tab/Cap	Metoz 2.5	10 Tab	4.40/1 Tab	Rupees Four Paise Forty Only	L-1
166	UNICURE INDIA LTD	2625	Taurine+Acetylcysteine Tab/Cap: Each Tab/Cap to contain Taurine (500mg) + Acetylcysteine (150mg)	1 Tab/Cap	Same as in Item	10 Tab	4.48/1 Tab	Rupees Four Paise Forty Eight Only	L-1
166	HAB Pharmaceuticals & Research Ltd	2626	NALTREXONE Tab/Cap: Each Tab/Cap to contains NALTREXONE 50mg	1 Tab/Cap	NALSIGN	10 Tab	44.40/1 Tab	Rupees Forty Four Paise Forty Only	L-1
166	MAAN PHARMACEUTICALS LTD.	2626	NALTREXONE Tab/Cap: Each Tab/Cap to contain NALTREXONE 50mg	1 Tab/Cap	Same as in Item	10 Tab	45.00/1 Tab	Rupees Forty Five Only	L-2
166	MICRON PHARMACEUTICALS	2626	NALTREXONE Tab/Cap: Each Tab/Cap to contain NALTREXONE 50mg	1 Tab/Cap	Same as in Item	10 Tab	49.50/1 Tab	Rupees Forty Nine Paise Fifty Only	L-3
166	Cipla Ltd.	2628	Nebivolol Tab/Cap: Each Tab/Cap to contain Nebivolol 2.5mg	1 Tab/Cap	NEBICIP 2.5	10 Tab	0.86/1 Tab	Paise Eighty Six Only	L-1
166	Aristo Pharmaceuticals Private Ltd.	2628	Nebivolol Tab/Cap: Each Tab/Cap to contain Nebivolol 2.5mg	1 Tab/Cap	Nebi 2.5	10 Tab	1.05/1 Tab	Rupee One Paise Five Only	L-2
166	Torrent Pharmaceuticals Ltd.	2628	Nebivolol Tab/Cap: Each Tab/Cap to contain Nebivolol 2.5mg	1 Tab/cap	NEBICARD-2.5 MG	15 Tab	1.16/1 Tab	Rupee One Paise Sixteen Only	L-3

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	MESMER PHARMACEUTICALS	2633	Oxcarbazepine Tab/Cap: Each Tab/Cap to contain Oxcarbazepine 300mg	1 Tab/Cap	Oxepin-300	10 Tab	3.48/1 Tab	Rupees Three Paise Forty Eight Only	L-1
166	LUPIN LIMITED	2633	Oxcarbazepine Tab/Cap: Each Tab/Cap to contain Oxcarbazepine 300mg	1 Tab/Cap	LOVAX 300	15 Tab	3.49/1 Tab	Rupees Three Paise Forty Nine Only	L-2
166	Macleods Pharmaceuticals Limited	2633	Oxcarbazepine Tab/Cap: Each Tab/Cap to contain Oxcarbazepine 300mg	1 Tab/Cap	CARBAMAC	10 Tab	3.71/1 Tab	Rupees Three Paise Seventy One Only	L-3
166	Intas Pharmaceuticals Ltd.	2635	Quetiapine Fumarate 300mg Tab/Cap: Each Tab/Cap to contain Quetiapine Fumarate 300mg	1 Tab/Cap	QUTAN-300	10 Tab	21.00/1 Tab	Rupees Twenty One Only	L-1
166	MICRO LABS LTD	2640	Telmisartan+Chlorthalidone Tab/Cap: Each Tab/Cap to contain Telmisartan 40mg + Chlorthalidone 12.5 mg	1 Tab/Cap	ARBITEL-CT 40	15 Tab	1.34/1 Tab	Rupee One Paise Thirty Four Only	L-1 (50% of Order Quantity)
166	Cipla Ltd.	2640	Telmisartan+Chlorthalidone Tab/Cap: Each Tab/Cap to contain Telmisartan 40mg + Chlorthalidone 12.5 mg	1 Tab/Cap	CRESAR CT 40	10 Tab	1.34/1 Tab	Rupee One Paise Thirty Four Only	L-1 (50% of Order Quantity)
166	Macleods Pharmaceuticals Limited	2640	Telmisartan+Chlorthalidone Tab/Cap: Each Tab/Cap to contain Telmisartan 40mg + Chlorthalidone 12.5 mg	1 Tab/Cap	MACSART CH 40	10 Tabs	1.51/1 Tab	Rupee One Paise Fifty One Only	L-2
166	Ipca Laboratories Ltd.	2640	Telmisartan+Chlorthalidone Tab/Cap: Each Tab/Cap to contain Telmisartan 40mg + Chlorthalidone 12.5 mg	1 Tab/Cap	CTD-T 12.5/40	15 Tab	1.57/1 Tab	Rupee One Paise Fifty Seven Only	L-3
166	Novo Nordisk India Private limited	2643	Anti Hemophilic Factor Concentrate VIII (r-DNA glycopegylated),500 IU vial with diluent	1 Vial/Amp	Esperoct 500IU (Mfd. by Novo Nordisk A/S, Denmark)	1 Vial	6990/1 Vial	Rupees Six Thousand Nine Hundred Ninety Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Novo Nordisk India Private limited	2644	Anti Hemophilic Factor Concentrate VIII (r-DNA glycopegylated),1000 IU vial with diluent	1 Vial/Amp	Esperoct 1000IU (Mfd. by Novo Nordisk A/S, Denmark)	1 Vial	13980/1 Vial	Rupees Thirteen Thousand Nine Hundred Eighty Only	L-1
166	Novo Nordisk India Private limited	2645	Anti Hemophilic Factor Concentrate VIII (r-DNA glycopegylated),2000 IU vial with diluent	1 Vial/Amp	Esperoct 2000IU (Mfd. by Novo Nordisk A/S, Denmark)	1 Vial	27960/1 Vial	Rupees Twenty Seven Thousand Nine Hundred Sixty Only	L-1
166	Bayer Pharmaceuticals Private Limited	2646	Vericiguat Tab:Each Tab to contain Vericiguat 2.5mg	1 Tab/Cap	Verquvo 2.5 mg (Mfd. by Bayer AG, Germany)	14 Tab	97.19/1 Tab	Rupees Ninety Seven Paise Nineteen Only	L-1
166	Bayer Pharmaceuticals Private Limited	2647	Vericiguat Tab:Each Tab to contain Vericiguat 5mg	1 Tab/Cap	Verquvo 5 mg (Mfd. by Bayer AG, Germany)	14 Tab	97.19/1 Tab	Rupees Ninety Seven Paise Nineteen Only	L-1
166	Pulse Pharmaceuticals Pvt Ltd	2649	Zolpidem+Melatonin Tab/Cap:Each Tab/Cap to contain Zolpidem 5mg+ Melatonin 3mg	1 Tab/Cap	Zolsoma 5	10 Tab	7.01/1 Tab	Rupees Seven Paise One Only	L-1
166	Intas Pharmaceuticals Ltd.	2650	Zonisamide Cap: Each Tab to contain Zonisamide 100mg Cap	1 Tab/Cap	ZONIMID-100	10 Cap	13.5/1 Cap	Rupees Thirteen Paise Fifty Only	L-1
166	Cipla Ltd.	1043b	Rotahaler Device - Rotahaler	1 piece	ROTAHALER	1 Unit	48.00/1 Unit	Rupees Forty Eight Only	L-1
166	MASCOT HEALTH SERIES PVT LTD	1061a	Glyceryl TrinitrateCR Tab/Cap- EachCR Tab/Captocontain : Glyceryl Trinitrate 2.6 mg.	1 Tab/Cap	NITROHEAL-2.6	30 Tab	0.67/1 Tab	Paise Sixty Seven Only	L-1
166	Windlas Biotech Limited	1061a	Glyceryl Trinitrate CR Tab/Cap - Each CR Tab/Cap to contain : Glyceryl Trinitrate 2.6 mg.	1 Tab/Cap	WINITRO 2.6	30 Tab	0.82/1 Tab	Paise Eighty Two Only	L-2

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	UNICURE INDIA LTD	1061a	Glyceryl Trinitrate CR Tab/Cap - Each CR Tab/Cap to contain : Glyceryl Trinitrate 2.6 mg.	1 Tab/Cap	Same as in Item	10 Tab	0.91/1 Tab	Paise Ninety One Only	L-3
166	Abbott Healthcare Pvt Ltd	1127b	Carbamazepin CR Tab/Cap- Each CR Tab/Cap to contain : Carbamazepin 400 mg	1 Tab/Cap	Mazetol SR 400	15 Tab	2.26/1 Tab	Rupees Two Paise Twenty Six Only	L-1
166	Intas Pharmaceuticals Ltd.	1127b	Carbamazepin CR Tab/Cap- Each CR Tab/Cap to contain : Carbamazepin 400 mg	1 Tab/Cap	ZEN RETARD-400	10 Tab	3.00/1 Tab	Rupees Three Only	L-2
166	STADMED PRIVATE LIMITED	1533a	Hydrochlorothiazide Tab/Cap- Each Tab/Cap to contain: Hydrochlorothiazide 12.5mg	1 Tab/Cap	BPZIDE 12.5	10 Tab	0.19/1 Tab	Paise Nineteen Only	L-1
166	Novo Nordisk India Private limited	1534a	Human Coagulation Factor VII Inj-Each vial to contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 1mg	1 Vial	NovoSeven 1mg (Mfd. by Novo Nordisk A/S, Denmark)	1 Vial	39310/1 Vial	Rupees Thirty Nine Thousand Three Hundred Ten Only	L-1
166	Novo Nordisk India Private limited	1534b	Human Coagulation Factor VII Inj-Each vial to contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 2mg	1 Vial	NovoSeven 2mg (Mfd. by Novo Nordisk A/S, Denmark)	1 Vial	78620/1 Vial	Rupees Seventy Eight Thousand Six Hundred Twenty Only	L-1
166	Biodeal Pharmaceuticals Ltd.	1539a	Betahistine hydrochloride/ Dihydrochloride Tab/Cap- Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 8mg	1 Tab/Cap	Same as in Item	10 Tab	0.27/1 Tab	Paise Twenty Seven Only	L-1
166	Morepen Laboratories Limited	1539a	Betahistine hydrochloride/ Dihydrochloride Tab/Cap- Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 8mg	1 Tab/Cap	VERTIDOC-8	10 Tab	0.31/1 Tab	Paise Thirty One Only	L-2

ESIC

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Abbott India Limited	1539a	Betahistine hydrochloride/ Dihydrochloride Tab/Cap: Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 8mg	1 Tab/Cap	Vertin	15 Tab	0.50/1 Tab	Paise Fifty Only	L-3
166	Biodeal Pharmaceuticals Ltd.	1539b	Betahistine hydrochloride/ Dihydrochloride Tab/Cap- Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 16mg	1 Tab/Cap	Betahistine Hydrochloride Tablets IP 16 mg	10 Tab	0.37/1 Tab	Paise Thirty Seven Only	L-1
166	Morepen Laboratories Limited	1539b	Betahistine hydrochloride/ Dihydrochloride Tab/Cap- Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 16mg	1 Tab/Cap	Vertidoc-16	10 Tab	0.44/1 Tab	Paise Forty Four Only	L-2
166	Wings Biotech LLP	1539b	Betahistine hydrochloride/ Dihydrochloride Tab/Cap- Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 16mg	1 Tab/Cap	WINHISTINE-16	10 Tab	0.44/1 Tab	Paise Forty Four Only	L-2
166	Abbott India Limited	1539b	Betahistine hydrochloride/ Dihydrochloride Tab/Cap- Each Tab/Cap to contain: Betahistine hydrochloride/ Dihydrochloride 16mg	1 Tab/Cap	Vertin 16	15 Tab	0.60/1 Tab	Paise Sixty Only	L-3
166	RIVPRA FORMULATION PVT. LTD.	1540a	Rosuvastatin Tab/Cap - Each Tab/Cap to contain: Rosuvastatin 10mg	1 Tab/Cap	Same as in Item	10 Tab	0.49/1 Tab	Paise Forty Nine Only	L-1
166	Morepen Laboratories Limited	1540a	Rosuvastatin Tab/Cap - Each Tab/Cap to contain: Rosuvastatin 10mg	1 Tab/Cap	Rosufine 10	10 Tab	0.53/1 Tab	Paise Fifty Three Only	L-2
166	Wings Biotech LLP	1540a	Rosuvastatin Tab/Cap - Each Tab/Cap to contain: Rosuvastatin 10mg	1 Tab/Cap	ROZUXIA-10	10 Tab	0.53/1 Tab	Paise Fifty Three Only	L-2

ESIC

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Healer's Lab	1540a	Rosuvastatin Tab/Cap -Each Tab/Cap to contain: Rosuvastatin 10mg	1 Tab/Cap	R-SAFE-10	10 Tab	0.53/1 Tab	Paise Fifty Three Only	L-2
166	MASCOT HEALTH SERIES PVT LTD	1540a	Rosuvastatin Tab/Cap - Each Tab/Cap to contain: Rosuvastatin 10mg	1 Tab/Cap	ROSUSTA-10	10 Tab	0.54/1 Tab	Paise Fifty Four Only	L-3
166	RIVPRA FORMULATION PVT. LTD.	1540b	Rosuvastatin Tab/Cap - Each Tab/Cap to contain: Rosuvastatin 20mg	1 Tab/Cap	Same as in Item	10 Tab	0.71/1 Tab	Paise Seventy One Only	L-1
166	HAB Pharmaceuticals & Research Ltd	1540b	Rosuvastatin Tab/Cap -Each Tab/Cap to contain: Rosuvastatin 20mg	1 Tab/Cap	ROVATIN-20	10 Tab	0.75/1 Tab	Paise Seventy Five Only	L-2
166	Morepen Laboratories Limited	1540b	Rosuvastatin Tab/Cap - Each Tab/Cap to contain: Rosuvastatin 20mg	1 Tab/Cap	Rosufine 20	10 Tab	0.78/1 Tab	Paise Seventy Eight Only	L-3
166	Cipla Ltd.	336a	Carvedilol Tab/Cap-Each Tab/Cap to contain: Carvedilol 3.125mg	1 Tab/Cap	CARLOC 3.125	15 Tab	0.26/1 Tab	Paise Twenty Six Only	L-1
166	Morepen Laboratories Limited	336a	Carvedilol Tab/Cap- Each Tab/Cap to contain: Carvedilol 3.125mg	1 Tab/Cap	Cardifine 3.125	10 Tab	0.34/1 Tab	Paise Thirty Four Only	L-2
166	Intas Pharmaceuticals Ltd.	336a	Carvedilol Tab/Cap- Each Tab/Cap to contain: Carvedilol 3.125mg	1 Tab/Cap	CARCA-3.125	15 Tab	2.40/1 Tab	Rupees Two Paise Forty Only	L-3
166	MICRO LABS LTD	341a	Iso-Sorbide Mononitrate SR Tab/Cap - Each SR Tab/Cap to contain: Iso-sorbide Mononitrate30mg.	1 Tab/Cap	Nitrofix SR 30	10 Tab	2.80/1 Tab	Rupees Two Paise Eighty Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Intas Pharmaceuticals Ltd.	341a	Iso-Sorbide Mononitrate SR Tab/Cap - Each SR Tab/Cap to contain: Iso-sorbide Mononitrate 30mg.	1 Tab/Cap	MONIT-30-SR	15 Tab	3.35/1 Tab	Rupees Three Paise Thirty Five Only	L-2
166	MICRO LABS LTD	341b	Iso-Sorbide Mononitrate SR Tab/Cap - Each SR Tab/Cap to contain: Iso-sorbide Mononitrate 60mg.	1 Tab/Cap	Nitrofix SR 60	10 Tab	3.60/1 Tab	Rupees Three Paise Sixty Only	L-1
166	Intas Pharmaceuticals Ltd.	341b	Iso-Sorbide Mononitrate SR Tab/Cap - Each SR Tab/Cap to contain: Iso-sorbide Mononitrate 60mg.	1 tab/cap	MONIT-60-SR	10 Tab	5.50/1 Tab	Rupees Five Paise Fifty Only	L-2
166	Intas Pharmaceuticals Ltd.	374b	Sertraline 50mg- Each Tab/Cap to contain: Sertraline 50mg Tab	1 Tab/Cap	SERTIMA-50	10 Tab	8.00/1 Tab	Rupees Eight Only	L-1
166	Cipla Ltd.	420b	Fluticasone + Salmeterol Inhaler - Each metered dose to contain: Salmeterol 25mcg. + Fluticasone 250mcg. (equal to or more than 120MDI)	1 Dose	SEROFLO INHALER 250	120 MDIs	0.68/1 MD	Paise Sixty Eight Only	L-1
166	Midas Care Pharmaceuticals Pvt. Ltd.	420b	Fluticasone + Salmeterol Inhaler - Each metered dose to contain: Salmeterol 25mcg. + Fluticasone 250mcg.(equal to or more than 120 MDI)	1 Dose	Flusal 250 Inhalation	240 MDIs	0.69/1 MD	Paise Sixty Nine Only	L-2
166	MICRO LABS LTD	433a	Sodium Valproate + Valproic Acid CR Tab/Cap -Each CR Tab/Cap to contain: (Sodium Valproate + Valproic Acid) eqv. to Sodium Valproate 200mg.	1 Tab/Cap	VALPRID-CR 200	15 Tab	1.41/1 Tab	Rupee One Paise Forty One Only	L-1
166	Intas Pharmaceuticals Ltd.	433a	Sodium Valproate 134 mg + Valproic Acid 58 mg CR TAB	1 Tab/Cap	VALPROL-CR-200	15 Tab	2.39/1 Tab	Rupees Two Paise Thirty Nine Only	L-2
166	Abbott India Limited	463a	Zolpidem Tab/Cap- Each Tab/Cap to contain: Zolpidem 5mg	1 Tab/Cap	Zolfresh 5	15 Tab	0.43/1 Tab	Paise Forty Three Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Primus Pharmaceuticals	463a	Zolpidem Tab/Cap-Each Tab/Cap to contain: Zolpidem 5mg	1 Tab/Cap	ZOLUS-5	10 Tab	0.88/1 Tab	Paise Eighty Eight Only	L-2
166	Ipca Laboratories Ltd.	463a	Zolpidem Tab/Cap-Each Tab/Cap to contain: Zolpidem 5mg	1 Tab/Cap	Sove-5	15 Tab	1.13/1 Tab	Rupee One Paise Thirteen Only	L-3
166	Abbott India Limited	463b	Zolpidem Tab/Cap-Each Tab/Cap to contain: Zolpidem 10mg.	1 Tab/Cap	Zolfresh 10	15 Tab	0.53/1 Tab	Paise Fifty Three Only	L-1
166	Primus Pharmaceuticals	463b	Zolpidem Tab/Cap-Each Tab/Cap to contain: Zolpidem 10mg.	1 Tab/Cap	ZOLUS-10	10 Tab	1.19/1 Tab	Rupee One Paise Nineteen Only	L-2
166	MICRO LABS LTD	463b	Zolpidem Tab/Cap-Each Tab/Cap to contain: Zolpidem 10mg.	1 Tab/Cap	ZOLPID-10	10 Tab	1.40/1 Tab	Rupee One Paise Forty Only	L-3
166	ZIM LABORATORIES LIMITED	470b	Perindopril Tab/Cap - Each Tab/Cap to contain: Perindopril 4mg	1 Tab/Cap	Zimpril-4	10 Tab	1.38/1 Tab	Rupee One Paise Thirty Eight Only	L-1
166	Hindustan Laboratories Limited	470b	Perindopril Tab/Cap -Each Tab/Cap to contain: Perindopril 4mg.	1 Tab/Cap	HINPRIL 4	10 Tab	1.43/1 Tab	Rupee One Paise Forty Three Only	L-2
166	Glenmark Pharmaceuticals Limited	470b	Perindopril Tab/Cap-Each Tab/Cap to contain: Perindopril 4mg.	1 Tab/Cap	PERIGARD-4	10 Tab	1.59/1 Tab	Rupee One Paise Fifty Nine Only	L-3
166	Biodeal Pharmaceuticals Ltd.	472a	Clonazepam Tab/Cap -Each Tab/Cap to contain: Clonazepam 0.50mg	1 Tab/Cap	Same as in Item	10 Tab	0.19/1 Tab	Paise Nineteen Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Intas Pharmaceuticals Ltd.	472a	Clonazepam Tab/Cap -Each Tab/Cap to contain: Clonazepam 0.50mg	1 Tab/Cap	ZAPIZ-0.5	20 Tab	2.20/1 Tab	Rupees Two Paise Twenty Only	L-2
166	STADMED PRIVATE LIMITED	473b	Resperidone Tab/Cap- Each Tab/Cap to contain: Resperidone 2mg	1 TAB/CAP	SKIZ 2	10 Tab	0.22/1 Tab	Paise Twenty Two Only	L-1
166	MICRO LABS LTD	473b	Resperidone Tab/Cap-Each Tab/Cap to contain: Resperidone 2mg	1 Tab/Cap	RISPOND-2	15 Tab	0.52/1 Tab	Paise Fifty Two Only	L-2
166	MESMER PHARMACEUTICALS	473b	Resperidone Tab/Cap-Each Tab/Cap to contain: Resperidone 2mg	1 Tab/Cap	Riscon-2	10 Tab	0.67/1 Tab	Paise Sixty Seven Only	L-3
166	MESMER PHARMACEUTICALS	474a	Olanzapine Tab/Cap-Each Tab/Cap to contain: Olanzapine 2.5mg.	1 Tab/Cap	Olzic-2.5	10 Tab	0.28/1 Tab	Paise Twenty Eight Only	L-1
166	Torrent Pharmaceuticals Ltd.	52b	Nifedipine SR Tab/Cap-Each SR Tab/Cap to contain: Nifedipine 20mg	1 Tab/Cap	CALCIGARD RETARD	10 Tab	0.92/1 Tab	Paise Ninety Two Only	L-1
166	Zydus Healthcare Limited	52b	Nifedipine SR Tab/Cap- Each SR Tab/Cap to contain: Nifedipine 20mg	1 Tab/Cap	Depin Retard	15 Tab	1.27/1 Tab	Rupee One Paise Twenty Seven Only	L-2
166	J B Chemicals & Pharmaceuticals Ltd	52b	Nifedipine SR Tab/Cap- Each SR Tab/Cap to contain: Nifedipine 20mg	1 Tab/Cap	NICARDIA RETARD 20	15 Tab	2.32/1 Tab	Rupees Two Paise Thirty Two Only	L-3
166	Intas Pharmaceuticals Ltd.	56a	Enalapril Maleate Tab/Cap : Each Tab/Cap to contain: Enalapril Maleate 2.5mg	1 Tab/Cap	ENAPRIL-2.5	15 Tab	1.53/1 Tab	Rupee One Paise Fifty Three Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Morepen Laboratories Limited	56b	Enalapril Maleate Tab/Cap : Each Tab/Cap to contain: Enalapril Maleate 5mg	1 Tab/Cap	Envapen 5	10 Tab	0.31/1 Tab	Paise Thirty One Only	L-1
166	USV Private Limited	56b	Enalapril Maleate Tab/Cap : Each Tab/Cap to contain: Enalapril Maleate 5mg	1 Tab/Cap	Nuril-5	10 Tab	0.60/1 Tab	Paise Sixty Only	L-2
166	Intas Pharmaceuticals Ltd.	56b	Enalapril Maleate Tab/Cap : Each Tab/Cap to contain: Enalapril Maleate 5mg	1 Tab/Cap	ENAPRIL-5	15 Tab	2.20/1 Tab	Rupees Two Paise Twenty Only	L-3
166	MICRON PHARMACEUTICALS	61a	Spironolactone Tab/Cap-Each Tab/Cap to contain: Spironolactone 25mg.	1 Tab/Cap	Same as in Item	10 Tab	1.95/1 Tab	Rupee One Paise Ninety Five Only	L-1
166	Signature Phytochemical Industries	68b	Ethamsylate tab/Cap-Each Tab/Cap to contain Ethamsylate 500 mg	1 Tab/Cap	ETHAMSIG	10 Tab	8.90/1 Tab	Rupees Eight Paise Ninety Only	L-1
166	Indoco Remedies Ltd.	68b	Etamsylatetab/Cap Each Tab/Cap to contain Ethamsylate 500 mg	1 Tab/Cap	Hemsyl-500	10 Tab	22.79/1 Tab	Rupees Twenty Two Paise Seventy Nine Only	L-2
166	Abbott Healthcare Pvt Ltd	72a	Acenocoumarol Tab/Cap - Each Tab/Cap to contain: Acenocoumarol 1mg	1 Tab/Cap	Acitrom 1	30 Tab	0.99/1 Tab	Paise Ninety Nine Only	L-1
166	Macleods Pharmaceuticals Limited	72a	Acenocoumarol Tab/Cap -Each Tab/Cap to contain: Acenocoumarol 1mg	1 Tab/Cap	ACENOMAC 1	10 Tab	2.32/1 Tab	Rupees Two Paise Thirty Two Only	L-2
166	STADMED PRIVATE LIMITED	94a	Alprazolam Tab/Cap- Each Tab/Cap to contain: Alprazolam 0.25mg	1 Tab/Cap	ZOLAM 0.25	10 Tab	0.13/1 Tab	Paise Thirteen Only	L-1

DG-ESIC Central Rate Contract No.166 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
166	Cipla Ltd.	94a	Alprazolam Tab/Cap-Each Tab/Cap to contain: Alprazolam 0.25mg	1 Tab/Cap	RESTYL 0.25mg	15 Tab	0.15/1 Tab	Paise Fifteen Only	L-2
166	Torrent Pharmaceuticals Ltd.	94a	Alprazolam Tab/Cap-Each Tab/Cap to contain: Alprazolam 0.25mg	1 Tab/Cap	ALPRAX-0.25	15 Tab	0.27/1 Tab	Paise Twenty Seven Only	L-3
166	Wings Biotech LLP	94b	Alprazolam Tab/Cap- Each Tab/Cap to contain: Alprazolam 0.5mg	1 Tab/Cap	Same as in Item	10 Tab	0.26/1 Tab	Paise Twenty Six Only	L-1
166	Cipla Ltd.	94b	Alprazolam Tab/Cap-Each Tab/Cap to contain: Alprazolam 0.5mg.	1 Tab/Cap	RESTYL 0.5mg	15 Tab	0.29/1 Tab	Paise Twenty Nine Only	L-2 (50% of Order Quantity)
166	Torrent Pharmaceuticals Ltd.	94b	Alprazolam Tab/Cap-Each Tab/Cap to contain: Alprazolam 0.5mg.	1 Tab/Cap	ALPRAX-0.50	15 Tab	0.29/1 Tab	Paise Twenty Nine Only	L-2 (50% of Order Quantity)
166	Intas Pharmaceuticals Ltd.	94b	Alprazolam Tab/Cap-Each Tab/Cap to contain: Alprazolam 0.5mg.	1 Tab/Cap	ZOLAX-0.5	10 Tab	2.96/1 Tab	Rupees Two Paise Ninety Six Only	L-3

END OF RATE CONTRACT

करा.बी.नि.
ESIC